f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom e roche finance report finance report finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sale chf chf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december definition cer core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business free cash flow concept fully describe page reconciliation ifrs cash flow free cash flow give therefinance brief roche roche group report good overall result sale core earning share grow constant exchange rate cer ifrs net income decrease significant impairment goodwill intangible asset sale group sale increase cer chf billion growth chf term pharmaceutical sale growth cer recently launch medicine ocrevus tecentriq alecensa oncology continue growth franchise sale avastin decrease competitive pressure immunology sale increase lead xolair actemraroactemra sale tamiflu fall generic competition entry biosimilar negative impact sale mabtherarituxan europe diagnostic sale show growth cer immunodiagnostic business major contributor operating result core operating profit increase cer chf billion increase chf term research development expenditure grow cer chf billion core basis focus oncology immunology therapeutic area research development cost represent group sale ifrs operating result include noncore expense pretax chf billion major factor chf billion impairment goodwill intangible asset chf billion amortisation intangible asset chf billion global restructuring plan notably pharmaceutical division strategic realignment manufacturing network nonoperate result finance cost ifrs decrease chf billion chf billion drive low interest expense low loss bond redemption income tax expense ifrs include transitional expense chf billion arising change tax rate core effective tax rate net income ifrs net income decrease cer chf billion decrease chf term core earning share increase cer chf term cash flow operate free cash flow increase significantly chf billion underlying cash generation division low net work capital low capital expenditure lead increase operate free cash flow cer chf term free cash flow increase cer chf term chf billion drive high operating free cash flow low pension contribution low interest pay financial position net working capital decrease cer high payable accrue liability low inventory offset increase receivables drive increase sale net debt decrease chf billion generate free cash flow offset dividend pay net debt percentage total asset credit rating strong moodys standard poor aa shareholder return dividend proposal increase dividend chf share represent st consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle noncurrent liability operate segment information current liability net financial expense provision contingent liability income taxis debt business combination equity attributable roche shareholder global restructuring plan subsidiary associate property plant equipment noncontrolle interest goodwill employee benefit intangible asset pension postemployment benefit inventory equity compensation plan account receivable earning share nonvoting equity security marketable security statement cash flow cash cash equivalent risk management noncurrent asset relate party current asset list subsidiary associate account payable significant accounting policy report roche management internal control financial report statutory auditor report general meeting roche holding ltd basel independent reasonable assurance report internal control financial report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning statutory auditor report general meeting roche holding ltd basel financial review roche group financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group result show sale growth constant exchange rate cer core operating profit core ep sale growth drive recently launch pharmaceutical product ocrevus tecentriq alecensa immunodiagnostic business diagnostic division group continue support development launch new product report growth core operating profit despite base effect income pension change result operate free cash flow chf billion increase cash generate business couple decrease net work capital low capital expenditure sale pharmaceutical division rise chf billion ocrevus tecentriq alecensa contribute chf billion new sale represent division growth oncology franchise sale increase chf billion lead perjeta mabtherarituxan sale chf billion growth globally despite sale europe lower follow biosimilar entry sale avastin chf billion decline competitive pressure sale immunology grow chf billion xolair actemraroactemra increase respectively sale tamiflu fall competition generic market diagnostic division sale grow major growth area centralise point care solution sale increase lead immunodiagnostic business ifrs operating profit stable pharmaceutical division diagnostic division division impact impairment charge goodwill intangible asset pharmaceutical core operating profit increase diagnostic remain stable operating profit growth rate division impact base effect income change group swiss pension plan pharmaceutical marketing distribution cost grow launch new product notably ocrevus tecentriq continue investment research development total chf billion group major area pharmaceutical oncology tecentriq cancer immunotherapy portfolio key driver immunology neuroscience diagnostic activity increasingly focus integrate core laboratory digitalise datum management project division acquire viewic software company focus laboratory business analytic operate free cash flow chf billion increase chf billion high cash generation business sale growth exceed increase cash expense furthermore net work capital decrease overall increase decrease mainly high payable partially offset high receivables capital expenditure decrease compare free cash flow chf billion increase chf billion high operating free cash flow low pension contribution low interest payment net income decrease cer ifrs basis increase core basis addition item describe core result ifrs result include intangible asset impairment charge total chf billion notably chf billion partial impairment esbriet product intangible asset impairment diagnostic sequence business chf billion roche finance report roche group financial review global restructuring expense chf billion line expense offset income chf billion reversal contingent consideration arrangement chf billion income release legal provision financing cost low decrease interest expense low loss bond redemption change tax rate effective january result transitional expense chf billion arise remeasurement group yearend defer tax position core ep increase cer line sale growth compare swiss franc weak euro european currency major currency asiapacific region partially offset strong swiss franc japanese yen swiss franc remain stable dollar net impact negligible result express swiss franc compare constant exchange rate sale core operating profit core eps income statement change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf page definition core result core ep roche finance report financial review roche group sale sale increase cer chf usd chf billion sale pharmaceutical division rise chf billion growth oncology immunology neuroscience therapeutic area key growth driver additional chf billion sale recently launch product ocrevus tecentriq alecensa new product represent division growth account division total sale mabtherarituxan sale chf billion growth drive growth biosimilar version launch eu market contribute decrease mabtherarituxan sales europe sales avastin chf billion decline competitive pressure franchise continue grow sale increase main driver growth increase global demand perjeta high herceptin sale notably immunology sale chf billion growth come actemra roactemra xolair sale tamiflu fall competition generic market diagnostic division record sale chf billion increase major growth area centralise point care solution represent division sale grow lead immunodiagnostic business divisional operating result pharmaceutical diagnostic corporate group chf chf chf chf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase roche finance report roche group financial review core operating result core operating profit group increase cer pharmaceutical division core operating profit increase diagnostic division stable chf billion income chf million pretax change group pension plan switzerland exclude item core operating profit group grow compare growth pharmaceutical division diagnostic division pharmaceutical division division core operating profit increase cer sale increase increase expenditure research development launch expense ocrevus tecentriq new product income product disposal income chf million compare chf million income pension plan change chf million diagnostic division core operating profit stable cer increase pension change exclude cost sale increase unfavourable product mix arise high instrument placement notably asiapacific region marketing distribution increase high spending emerge market especially china general administration increase income pension change base effect chf million acquisition group acquire control interest mysugr gmbh develop lead mobile diabetes platform market total cash consideration chf million addition group acquire control interest viewic inc consideration chf million viewic software company focus laboratory business analytic december group announce agreement fully acquire ignyta inc total transaction value usd billion chf million noncore income contingent consideration provision mainly reversal remain provision relate seragon acquisition partial reversal provision relate dutalys trophos acquisition impairment charge chf million related acquisition note impairment goodwill intangible asset commentary chf million noncore income contingent consideration provision relate intangible asset impairment charge chf million noncore cost include expense chf million release esbriet inventory fair value adjustment fully unwound mid detail give note annual financial statement global restructuring plan group initiate resource flexibility plan pharmaceutical division address future challenge include biosimilar competition area plan include biologic manufacturing commercial operation product development strategy group continue implementation major global restructuring plan initiate prior year notably strategic realignment pharmaceutical division manufacturing network programme address longterm strategy diagnostic division roche finance report financial review roche group global restructuring plan cost incur millions chf diagnostic site consolidation plan total global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost include strategy plan diagnostic division diabetes care autonomy speed plan include pharmaceutical division strategic realignment manufacture network resource flexibility biologic manufacturing network include plan resource flexibility pharmaceutical division commercial operation global product developmentstrategy organisation diagnostic division strategy plan diagnostic division launch incur cost chf million mainly employeerelate cost spend small plan division chf million include cost relate autonomy speed initiative diabetes care certain project site consolidation november pharmaceutical division announce strategic realignment manufacturing network include exit manufacture site clarecastle ireland legans spain segrate italy florence cost plan chf million chf million noncash writedown accelerate depreciation property plant equipment employeerelate provision reverse likely scenario segrate site change closure divestment divestment florence segrate legan site complete result total cost chf million include chf million accumulate currency translation loss consolidation transfer income statement expect cost environmental remediation clarecastle site reassess result increase provision environmental remediation plan include resource flexibility biologic manufacturing network result headcount reduction kaiseraugst site switzerland exit small molecule manufacturing site toluca mexico global restructuring plan major item chf million resource flexibility pharmaceutical division include global field force reduction notably europe remain chf million include plan outsource function share service centre external provider detail give note annual financial statement impairment goodwill intangible asset impairment charge chf million pharmaceutical division large item charge chf million partial impairment esbriet product intangible acquire intermune acquisition impairment charge record half intangible asset follow lowerthanexpected sale esbriet half relative recent longterm forecast revise longterm forecast prepare second half reduction sale expectation result additional impairment charge charge chf million writeoff goodwill relate seragon acquisition decision stop development backup compound acquire addition impairment chf million relate compound acquire trophos acquisition arise launch competitor product impairment chf million decision stop development compound alliance partner follow assessment clinical nonclinical datum relate decrease contingent consideration provision mainly seragon trophos dutalys acquisition contribute income chf million note acquisition commentary roche finance report roche group financial review diagnostic division record impairment charge chf million major sequence business impairment charge chf million goodwill chf million product intangible asset acquire ariosa acquisition impairment late longterm forecast project decrease forecast cash flow change assumption market penetration pricing reimbursement revise time market single molecule sequence technology addition molecular diagnostic business partial impairment chf million record product intangible asset acquire geneweave acquisition decrease forecast cash flow follow change timeline future product development update market size assumption detail give note annual financial statement pension postemployment benefit operating income chf million record past service cost change group pension plan switzerland announce june represent onetime impact adjustment pension liability plan change chf million record pharmaceutical division chf million diagnostic division chf million corporate aftertax impact chf million matter base effect growth rate show result information group pension postemployment benefit give note annual financial statement legal environmental case base development litigation notably accutane case provision previously hold release result income chf million expect cost environmental remediation clarecastle site ireland reassess result increase provision environmental remediation significant development impact financial result detail give note annual financial statement treasury taxation core financing cost chf million decrease low interest expense low interest cost pension plan low loss bond redemption core financial income chf million include net income equity security chf million partly offset net foreign exchange loss chf million core tax expense increase chf billion low increase profit tax group effective core tax rate decrease compare largely mix effect manufacture supply chain december change tax rate enact effective january change decrease federal tax rate result transitional expense chf million arise remeasurement group defer tax position treat noncore item new rate apply exclude transition impact group effective core tax rate percentage term low twenty roche finance report financial review roche group net income earning share ifrs net income decrease swiss franc term cer dilute eps decrease swiss franc term cer core net income increase core eps increase cer core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset alliance business combination cost core eps increase exclude base impact change group swiss pension plan net income change change chf chf chf cer ifrs net income reconcile item net tax global restructuring plan intangible asset amortisation goodwill intangible asset impairment alliance business combination legal environmental case pension plan settlement transitional effect change tax rate normalisation equity compensation plan tax benefit core net income supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result financial position financial position change change chf chf chf cer pharmaceutical net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start year swiss franc depreciate significantly euro positive translation impact balance sheet position appreciation swiss franc dollar negative translation impact net operating asset offset group level natural hedge group dollardenominate debt exchange rate give roche finance report roche group financial review pharmaceutical division net working capital decrease cer major driver high liability sale rebate chargeback factor inventory writeoff decrease inventory level certain mature product partly offset high inventory launch product offset increase trade receivable high sale extend postlaunch payment term ocrevus longterm net operating asset low chf billion impairment intangible asset diagnostic division decrease net work capital cer drive increase payable high liability pende rebate inventory decrease inventory optimisation initiative high demand decrease trade payable follow low spending trade receivables increase high sale longterm net operating asset decrease low goodwill intangible asset partially offset high property plant equipment low provision decrease net debt free cash flow chf billion partly offset dividend payment chf billion net pension liability decrease chf billion chf billion improved asset performance net tax liability decrease mainly defer tax impact impairment intangible asset partially offset defer tax impact change tax rate announce late free cash flow free cash flow change change chf chf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay free cash flow definition free cash flow detailed breakdown page group operate free cash flow chf billion increase chf billion cer reflect high cash generation business improve operating result sale growth exceed cash operating expense development operate free cash flow positively impact net work capital decrease increase decrease mainly high payable partially offset high receivables base impact inventory buildup repeat contribute yearonyear growth operate free cash flow capital expenditure lower comparative period free cash flow chf billion increase chf billion compare high operating free cash flow low pension contribution low interest payment roche finance report financial review roche group pharmaceutical division operating result pharmaceutical division operating result change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result page definition free cash flow sale overview pharmaceutical division sale therapeutic area change sale sale chf chf cer oncology immunology neuroscience ophthalmology infectious disease therapeutic area total sale pharmaceutical division sale increase cer chf billion growth oncology immunology neuroscience therapeutic area main product drive growth recently launch medicine ocrevus tecentriq alecensa contribute chf billion cer new sale new product represent division growth account division total sale significant growth driver perjeta xolair actemraroactemra herceptin mabtherarituxan growth lead immunology biosimilar version mabtherarituxan launch eu market mid lead decrease sale europe avastin sale decline competitive pressure sale tamiflu fall generic competition roche finance report roche group financial review ocrevus launch april good uptake sale chf billion growth tecentriq sale drive mainly uptake metastatic urothelial carcinoma metastatic nonsmall cell lung cancer alecensa sale higher lead japan franchise continue grow sale increase main driver growth increase global demand perjeta neoadjuvant metastatic setting herceptin sale higher notably sale increase immunology come xolair increase use actemraroactemra europe product sale pharmaceutical division sale change sale sale chf chf cer oncology herceptin avastin mabtherarituxan perjeta kadcyla tarceva tecentriq xeloda alecensa gazyvagazyvaro total oncology immunology actemraroactemra xolair mabtherarituxan esbriet pulmozyme cellcept total immunology neuroscience ocrevus madopar total neuroscience ophthalmology lucentis total ophthalmology infectious disease tamiflu rocephin valcytecymevene pegasys total infectious disease therapeutic area activasetnkase mircera neorecormonepogin total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology franchise roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid arthritis ra certain type antineutrophil cytoplasmic antibody anca associate vasculitis mabtherarituxan regional sale change sale sale chf chf cer united states europe japan international total sale sale higher drive growth immunology segment mabtherarituxan widely nearly approve indication sale increase sale high international region particularly brazil high government sale sale europe fall drive launch biosimilar eu market year franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sale change sale sale chf chf cer united states europe japan international total sale perjeta regional sale change sale sale chf chf cer united states europe japan international total sale kadcyla regional sale change sale sale chf chf cer united states europe japan international total sale franchise grow chf billion herceptin sale higher drive growth mainly continue growth early metastatic breast cancer continue growth europe drive sale growth uk italy perjeta sale grow region follow increase demand neoadjuvant metastatic setting kadcyla sale increase especially international region uptake turkey significant factor roche finance report roche group financial review avastin advance colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma type brain tumour avastin regional sale change sale sale chf chf cer united states europe japan international total sale overall sale prior year sale decrease competition immunotherapy medicine lung cancer europe sale decline mainly drive delist metastatic breast cancer france sale grow international region particular china sale increase broad market penetration lung colorectal cancer set japan sale increase increase volume growth partially offset negative impact biannual government price cut actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sale change sale sale chf chf cer united states europe japan international total sale sale increase growth region drive continued uptake subcutaneous formulation xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sale change sale sale chf chf cer united states total sale sale grow drive market expansion outpace competitive erosion allergic asthma continue growth chronic idiopathic urticaria ocrevus relapse form multiple sclerosis rm primary progressive multiple sclerosis ppm ocrevus regional sale change sale sale chf chf cer united states europe international total sale ocrevus approve sale food drug administration fda march show strong uptake launch ocrevus approve european union rm ppms january roche finance report financial review roche group lucentis wet agerelate macular degeneration wet amd macular oedema follow retinal vein occlusion rvo diabetic macular oedema dme lucentis regional sale change sale sale chf chf cer united states total sale sale increase mainly drive launch prefille syrinx growth new indication diabetic retinopathy dr myopic choroidal neovascularisation mcnv activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sale change sale sale chf chf cer united states international total sale sale higher lead mainly increase penetration eligibility treatment centre tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sale change sale sale chf chf cer united states europe japan international total sale sale low decline sale mainly europe international region increase competitive pressure pharmaceutical division sale region change sale sale chf chf cer united states europe japan international eemea latin america asiapacific region total sale eastern europe middle east africa united states sale grew lead uptake follow launch ocrevus tecentriq xolair sale activase tnkase sale increase patient uptake franchise mabtherarituxan continue grow respectively tamiflu sale decline mainly competition generic sales avastin fall competition immunotherapy medicine lucentis sale broadly stable sale tarceva low competitive pressure mandatory discount hospital b drug discount program increase low rate mainly high utilisation oncology product roche finance report roche group financial review europe sale decrease mainly low mabtherarituxan sale drive competition biosimilar version launch eu market franchise continue grow drive perjeta sale especially uk spain actemraroactemra sale increase grow demand subcutaneous formulation avastin sale decrease primarily result delist metastatic breast cancer france tamiflu sale europe low base effect governmental order uk japan sale grow alecensa sale increase proceed market penetration tamiflu actemra roactemra osteoporosis medicine edirol grew partially offset low sale establish product international sale increase drive latin america asiapacific sale china mainly grow additional reimbursement broad market penetration avastin sale brazil increase lead herceptin see high demand russia sale decline result competition noncomparable biologic herceptin pharmaceutical division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale competition generic medicine biosimilar group pharmaceutical product generally protect patent right intend provide group exclusive marketing right country patent right vary scope duration group required enter costly litigation enforce patent intellectual property right loss market exclusivity major product patent expiration challenge generic medicine biosimilar noncomparable biologic reason material adverse effect group business result operation financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically result significant reduction net sale relevant product manufacturer typically offer version low price patent expiry integral group business model future growth remain driven innovation late information clinical study include annual report page detail group product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm product sale affect recent patent expiry change chf chf cer comment tamiflu patent expiry major market pegasys patent expiry major market valcytecymevene patent expiry major market intellectual property biologic involve multiple patent patent timeline individual product difficult exact date patent expiry biologic medicine group currently estimate basic primary patent major biologic medicine begin expire follow mabtherarituxan mid herceptin mid avastin mid eu subcutaneous formulation mabtherarituxan herceptin secondary patent right roche finance report financial review roche group composition matter patent mabtherarituxan herceptin eu expire biosimilar version mabtherarituxan launch eu market mid major driver sale decline europe product sale affect biosimilar launch change chf chf cer comment mabtherarituxan europe biosimilar launch mid base publicly available information competitor company group currently anticipate follow potential development uncertainty surround specific biosimilar version group biologic medicine approve food drug administration biosimilar version mabtherarituxan come market mid end europe biosimilar version herceptin come market half japan biosimilar version mabtherarituxan approve list late biosimilar version herceptin come market japan sales mabtherarituxan herceptin avastin disclose previous section include regional breakdown operating result pharmaceutical division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis increase cer mainly high income product disposal include sale worldwide right bonviva bondronat exclude japan dilatrend kytril exclude japan royalty income increase mainly net increase sale royalty portfolio partly offset expiration royalty bear eylea patent income outlicense agreement increase outlicense lebrikizumab right pharmaceutical division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset business combination inventory fair value adjustment total ifrs basis core cost increase cer percentage sale cost sale increase percentage point manufacturing cost sale grow line sale growth increase cost new manufacturing facility bring online recent year partly offset low inventory writeoff royalty expense high ocrevus sale noncore cost include amortisation intangible asset mainly relate esbriet product intangible acquire intermune acquisition result additionally include chf million impairment esbriet intangible lower thanexpecte sale esbriet reduction sale expectation late longterm forecast result include final fair value unwind adjustment chf million acquire esbriet inventory roche finance report roche group financial review pharmaceutical division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer percentage sale remain stable cost incur ensure increase patient access launch ocrevus tecentriq hemlibra product restructuring cost relate resource flexibility initiative sale affiliate pharmaceutical division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer percentage sale decrease percentage point oncology franchise remain primary area research development tecentriq cancer immunotherapy portfolio key driver neuroscience immunology significant area spend earlystage research latestage development addition pharmaceutical division inlicense pipeline compound technology total value chf million chf million capitalise intangible asset impairment charge chf million include impairment chf million compound acquire trophos acquisition arise launch competitor product impairment chf million decision stop development compound alliance partner follow assessment clinical nonclinical datum impairment total chf million record follow writeoff intangible asset acquire dutalys santaris acquisition pharmaceutical division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset alliance business combination legal environmental case pension settlement gain loss total ifrs basis core cost increase cer percentage sale increase income pension change chf million exclude core cost increase mainly high legal service cost high personnel cost division impairment consist writeoff chf million goodwill decision stop development backup compound acquire seragon acquisition alliance business combination income include reversal contingent consideration provision seragon trophos dutaly acquisition global restructuring cost primarily relate divestment florence segrate legan site roche finance report financial review roche group roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale pharmaceutical division total core operating profit operating profit include elimination chf minus million unrealised intercompany gain roche pharmaceutical chugai chf plus million decrease exchange rate japanese yen negative impact chugai result express swiss franc sale chugai party increase japanese yen sale division increase japanese yen chugai core operating profit increase high sale milestone income partially offset increase research development cost high general administration cost operate free cash flow chugai increase chf million decrease inventory high operating profit financial position pharmaceutical division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc appreciate dollar result negative translation impact net operating asset partially offset positive translation impact euro swiss franc depreciate exchange rate give roche finance report roche group financial review net work capital net working capital decrease low inventory high net liability receivables payable inventory decrease inventory writeoff low inventory level certain mature product partly offset high inventory launch product net liability receivablespayable increase high accrual sale rebate chargeback payroll accrue liability include chf million genentech property purchase option exercise obligation july partially offset effect trade receivable increase high sale extend payment term ocrevus longterm net operating asset overall longterm net operating asset decrease goodwill intangible asset decrease significant impairment record capital expenditure include manufacture investment germany chugai japan site development basel kaiseraugst site switzerland south san francisco campus provision decrease follow reversal contingent consideration legal provision utilisation restructure provision longterm net asset increase reclassification longterm shortterm chf million liability genentech property purchase option exercise obligation july free cash flow pharmaceutical division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale page definition free cash flow detailed breakdown pharmaceutical division operate free cash flow increase chf billion main contribution come operate profit net operating cash adjustment increase cer high increase core operating profit base effect income pension change net work capital absorb cash start year mainly high payable partially offset high receivables reduction balance sheet inventory come noncash effective writedown buildup inventory occurred repeat contribute yearonyear growth operate free cash flow capital expenditure chf billion major item describe financial position section capital expenditure investment intangible asset lower contribute yearonyear growth operate free cash flow roche finance report financial review roche group diagnostic division operating result diagnostic division operating result change change chf chf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result page definition free cash flow sale diagnostic division continue increase sale growth cer chf billion centralised point care solution sale growth main contributor lead immunodiagnostic business molecular diagnostic sale increase mainly drive biochemical reagent molecular diagnostic instrument human papillomavirus hpv screening diabetes care sale decrease continued challenging market condition growth tissue diagnostic drive advanced stain product portfolio diagnostic division sale business area change sale sale chf chf cer centralise point care solution diabetes care molecular diagnostic tissue diagnostic total sale roche finance report roche group financial review centralise point care solution increase sale business area major contributor divisional sale performance growth primarily drive immunodiagnostic business represent divisional sale sale growth support clinical chemistry business regionally sale grow asiapacific growth china sale growth report europe middle east africa emea region mainly immunodiagnostic business centralise point care solution regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale diabete care sale decrease continuation challenge market condition lead decline north america sale decrease emea competitive pressure increase reimbursement competitor system continuous glucose monitor notably germany sale growth rest world drive new business latin america argentina brazil asiapacific china india diabetes care regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale molecular diagnostic overall sale rise growth underlie molecular business sale sequence business reporting decrease mainly market growth molecular business sale come mainly biochemical reagent molecular diagnostic instrument human papillomavirus hpv screen regional growth lead asiapacific notably china emea molecular diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale tissue diagnostic sale rise drive growth advance stain portfolio growth companion diagnostic growth primary stain business regionally sale asiapacific grow china main growth factor tissue diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale roche finance report financial review roche group diagnostic division sale region change sale sale chf chf cer europe middle east africa emea north america asiapacific latin america japan total sales emea region division large market main driver sale increase centralise point care solution north america sale stable sale growth tissue diagnostic centralise point care solution fully offset low sale diabetes care business fall continue price pressure sale increase asiapacific mainly china grow latin america sale rise new tender business local inflationary price increase sale growth japan lead centralised point care solution business diagnostic division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale operating result diagnostic division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis increase cer increase royalty income mainly patent dispute combine additional income new licence agreement diagnostic division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer drive unfavourable product mix high instrument placement notably asiapacific region remainder increase arise high depreciation place instrument core cost sale ratio increase impairment charge relate partial impairment sequence business intangible asset acquire ariosa acquisition global restructuring cost mainly relate site closure cost initiative harmonise process system roche finance report roche group financial review diagnostic division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer primarily increased spending emerge market asiapacific region especially china emea region core basis marketing distribution cost percentage sale stable global restructuring cost mainly organisational change divisional strategy plan diagnostic division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer increase spending integrate core laboratory digitalise datum management project partially offset decrease spending diabete care molecular diagnostic blood screen hpv percentage sale research development core cost decrease impairment charge relate partial impairment molecular diagnostic intangible asset acquire geneweave acquisition diagnostic division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset alliance business combination legal environmental case pension settlement gain loss total ifrs basis core cost increase cer compare base effect income change group swiss pension plan exclude effect core general administration cost increase administration cost increase cost additional headcount notably china creation new legal entity diabetes care business business taxis include income settlement agreement medical device excise tax general item include income underspend infrastructure area percentage sale core cost increase impairment relate goodwill sequence business legal expense mainly arise increase litigation cost sequence business roche finance report financial review roche group financial position diagnostic division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc depreciate significantly euro result positive translation impact net operating asset offset appreciation swiss franc dollar exchange rate give net work capital net trade working capital increase cer trade receivables increase drive sale increase inventory decrease inventory optimisation initiative high demand trade payable decrease low spending net liability receivablespayable increase high liability sale rebate longterm net operating asset longterm net operating asset decrease cer low goodwill intangible asset partially offset high property plant equipment low provision decrease goodwill intangible asset impairment sequence business molecular diagnostic property plant equipment increase high instrument placement manufacturing site expansion china germany provision decrease follow payment milestone relate recent acquisition roche finance report roche group financial review free cash flow diagnostic division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale definition free cash flow detailed breakdown page operate free cash flow diagnostic division net cash inflow chf million compare chf million cash generation business measure operating profit net operating cash adjustment increase line sale growth buildup net working capital notably inventory repeat contribute yearonyear growth operate free cash flow capital expenditure chf billion major item describe financial position section capital expenditure lower include significant site expansion roche finance report financial review roche group corporate operating result corporate operating result summary change chf chf cer administration pension past service cost business taxis capital taxis general item general administration cost core basis global restructuring plan alliance business combination legal environmental case total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result page definition free cash flow detailed breakdown general administration cost increase cer core basis drive base effect income pension change exclude core cost high impairment corporate asset increase personnel relate cost corporate project activity total cost ifrs basis increase include restructuring expense offset legal environmental cost change net operating asset utilisation provision ongoing environmental remediation activity nutley grenzach germany impairment asset corporate operating free cash flow show high outflow broadly line growth core cost exclude impact pension plan change roche finance report roche group financial review foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer chf change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy compare swiss franc weak euro european currency major currency asiapacific region partially offset swiss franc strong japanese yen swiss franc remain stable dollar net impact negligible result express swiss franc compare constant exchange rate sale core operating profit core ep sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact increase average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yen roche finance report financial review roche group treasury taxation result treasury taxation result change change chf chf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position net debt pension income taxis financial noncurrent asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury activity taxis pay total page definition core result page definition free cash flow financing cost core financing cost chf million decrease cer compare interest expense include amortisation debt discount issue cost decrease chf million chf million continue repayment refinance debt low interest rate loss bond redemption chf million compare chf million net interest cost define benefit pension plan decrease cer chf million mainly low discount rate germany end analysis financing cost give note annual financial statement detail debt repayment redemption give note roche finance report roche group financial review financial income expense core financial income expense net income chf million compare net income chf million low foreign exchange loss high net income equity security net foreign exchange result reflect hedging cost loss unhedged position net loss chf million compare net loss chf million core net income equity security chf million compare chf million analysis financial income expense give note annual financial statement income taxis group effective core tax rate decrease percentage point largely mix effect manufacture supply chain ifrs result increase effective tax rate percentage point mainly transitional effect change tax rate describe noncore result include significant goodwill impairment tax deductible ifrs result include noncore income release contingent consideration provision taxable net tax effect alliance business combination line table change tax rate enact december effective january change decrease federal tax rate group carry remeasurement defer tax position consequence net defer tax asset record balance sheet reduce chf million end result transitional expense chf million treat noncore item remain adjustment chf million record comprehensive income far relate temporary difference arise item record comprehensive income actuarial gainslosse pension plan new rate apply exclude transition impact group effective core tax rate percentage term low twenty detail group income tax expense relate balance sheet position give note annual financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate chf chf chf chf group effective tax rate core basis global restructuring plan goodwill intangible asset alliance business combination legal environmental case transitional effect change tax rate normalisation equity compensation plan tax benefit group effective tax rate ifrs basis financial position decrease net debt free cash flow chf billion partly offset dividend payment chf billion net pension liability decrease improved asset performance net tax liability decrease mainly defer tax impact impairment intangible asset partially offset defer tax impact change tax rate announce late december group hold financial longterm asset market value chf billion consist holding biotechnology pharmaceutical company acquire licensing transaction scientific collaboration compare start year swiss franc appreciate dollar positive translation impact group net debt dollardenominate debt translate low swiss franc yearend roche finance report financial review roche group free cash flow cash outflow treasury activity decrease chf billion low pension contribution low interest payment base effect investment financial longterm asset total taxis pay chf billion high tax payment cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay free cash flow definition free cash flow detailed breakdown page operate free cash flow increase chf billion cer chf billion major factor significant increase growth underlie cash generate operation increase chf billion low net work capital contribute overall operate free cash flow compare increase net working capital especially impact yearonyear growth rate addition capital expenditure low cash outflow treasury activity go chf billion low pension contribution low interest payment base effect high investment financial longterm asset taxis pay high chf billion high tax payment free cash flow chf billion significantly high high operating free cash flow low net cash outflow treasury operation roche finance report roche group financial review net debt millions chf january cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow dividend payment transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt december cash cash equivalent marketable security longterm debt shortterm debt net debt end period definition net debt net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euro swap dollar consolidated result economic characteristic equivalent dollardenominate bond note net debt position group december chf billion decrease chf billion december decrease strong free cash flow partly offset dividend payment chf billion issuance redemption repurchase bond note note annual financial statement impact liquid fund impact net debt position roche finance report financial review roche group contractual obligation commitment group obligation commitment set table carry value show consolidated balance sheet potential obligation show discount riskadjuste amount denominate foreign currency translate swiss franc december exchange rate contractual obligation commitment december millions chf potential obligation undiscounte carry year year year year total value onbalance sheet debt bond note debt contingent consideration provision account payable derivative financial instrument unfunde define benefit plan total onbalance sheet commitment offbalance sheet capital commitment property plant equipment operating lease contract manufacturing commitment alliance collaboration commitment total offbalance sheet commitment total contractual commitment reference note annual financial statement debt consist mainly bond note include principal interest group debt instrument debt mainly commercial paper carry value discount base interest rate inherent instrument contingent consideration provision potential payment arise business combination carry value risk adjust discount unfunded define benefit plan mainly pension plan group german affiliate fully reserve pension obligation invest local affiliate operation carry value discount future company contribution group fund plan show table capital commitment property plant equipment noncancellable commitment purchase construction mainly roche site basel switzerland mannheim germany south san francisco chugai site operating lease future obligation noncancellable lease contract group implement ifrs lease point obligation report balance sheet contract manufacturing commitment future minimum takeorpay commitment purchase inventory arise group major longterm agreement external contract manufacturing organisation cmos alliance collaboration commitment potential upfront milestone payment group inlicense arrangement potential payment alliance partner asset deal year include assume project currently development successful potential payment year include asset deal provision legal environmental matter include table timing cash outflow uncertain contingent development matter question roche finance report roche group financial review pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource define benefit plan operate income chf million record past service cost change group pension plan switzerland represent impact adjustment pension liability plan change announce expense group define benefit plan chf million exclude past service cost chf million base revise actuarial assumption end expense group define benefit plan expect approximately chf million line estimate pension expense include settlement past servicecurtailment effect arise year funding status balance sheet position chf chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group fund define benefit plan increase compare start year plan asset increase chf billion drive high return asset partially offset item include settlement payment ireland fund status pension fund monitor local pension fund governance body closely review group level additional contribution pay group pension plan uk total cash outflow group define benefit plan chf million compare chf million include additional contribution pay group pension plan switzerland ireland year unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation unfunded liability plan increase chf million mainly currency translation effect increase euro swiss franc year detail group pension postemployment benefit give note annual financial statement roche finance report financial review roche group roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate cer roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group chf term cer healthcare sector experience positive performance world market drive recovery global economy normalisation monetary policy eu gradual expect swiss market index smi post gain performance mixed relative major global index currency movement continue influence investor exposure swiss equity smi underperform major index outperform european index context positive readout end roche share performance continues impact investor concern biosimilar impact competition cancer immunotherapy peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index roche finance report roche group financial review propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting st consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security chf billion chf billion result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note annual financial statement payout ratio calculate dividend share divide core earning share roche finance report financial review roche group debt debt redemption follow redemption date march chf million bond date september usd million bond november group complete tender offer repurchase eur million note march gbp million note august debt issuance follow issuance march group issue chf million bond september chf million bond september chf million bond march transaction describe note annual financial statement maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf total total translate december exchange rate proceed bond note eur million swap dollar consolidated result bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation free cash flow chf billion include cash generate operation payment interest tax shortterm financing requirement group commercial paper programme issue usd billion unsecured commercial paper note commit credit line usd billion available backstop line commercial paper note total usd billion outstanding december usd billion longerterm financing group maintain strong longterm investmentgrade credit rating aa standard poor moodys facilitate efficient access international capital market information group debt give note annual financial statement credit rating roche group december shortterm longterm outlook moodys p stable standard poor aa stable roche finance report roche group financial review financial risk december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security chf total chf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group chf billion cash fix income marketable security remain strong invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables chf billion begin financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivables eur billion chf billion public customer country increase compare december euro term substantial collection late prior year end group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action group trade receivable balance southern europe decrease euro term liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group good cash generation ability future cash flow repay debt instrument come year roche enjoy strong longterm investmentgrade credit rating aa standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating overall creditworthiness roche group permit efficient access international capital market include commercial paper market group commit credit line financial institution total usd billion available backstop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var remain stable interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interestraterelated exposure financial result information financial risk management financial risk var methodology include note annual financial statement roche finance report financial review roche group international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement minor amendment exist standard interpretation material impact group overall result financial position new revise standard apply group assess expect impact new revise standard interpretation mandatory january group apply summarise group anticipate material impact group overall result financial position furthermore restatement comparative result necessary new standard apply note annual financial statement detail ifrs financial instrument group implement new standard effective january apply exemption retrospective application classification measurement requirement include impairment mean comparative result restate new standard applied standard deal classification recognition measurement include impairment financial instrument impairment financial asset include trade lease receivables introduce new hedge accounting model ifrs revenue contract customer group implement new standard effective january apply retrospective method transition new standard change amount revenue recognise restatement comparative result necessary new standard contain new set principle recognise measure revenue new requirement relate presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration receive exchange good service new revise standard apply ifrs lease group implement new standard effective january apply cumulative catchup method option transition mean comparative result restate new standard apply main impact new standard bring operating lease onbalance sheet group assess potential impact currently anticipate new standard result carry value lease asset increase approximately chf billion lease liability increase similar date implementation application new standard result currently report operating lease cost record interest expense give lease involve prevail low interest rate environment group currently expect effect material note annual financial statement detail matter roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group consolidate financial statement roche group roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income remeasurement define benefit plan item reclassify income statement availableforsale investment cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche finance report roche group consolidate financial statement roche group roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale equity security debt security purchase equity security debt security sale purchase money market instrument time account month net invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change noncontrolle interest equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december group expand presentation invest cash flow relate marketable security sale purchase money market instrument time account month show separately net basis comparative period information restate accordingly roche finance report roche group consolidate financial statement roche group roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist multiple component occur different time group party outlicense agreement involve upfront milestone payment occur year involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim relate sale december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country provision accrual relate pharmaceutical business amount chf million chf million relate expect sale return estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment december group chf million provision doubtful receivable note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account current economic condition business combination group initially recognise fair value identifiable asset acquire liability assume non control interest consideration transfer business combination management judgement particularly involve recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term roche finance report note roche group consolidate financial statement roche group impairment december group chf million property plant equipment note chf million goodwill note chf million intangible asset note goodwill intangible asset available use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lowerthananticipate product sale lead short useful life impairment pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation chf million note actuarial assumption differ materially actual result change market economic condition long short life span participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate december group chf million legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress reliable estimate provision record contingent liability disclose material environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision note total potential payment contingent consideration arrangement business combination chf million note estimate amount provide expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario develop income taxis december group current income tax net liability chf million defer tax net asset chf million note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation tax position uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term roche finance report roche group note roche group consolidate financial statement operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis pension fund management legal safety environmental service subdivisional information roche pharmaceutical chugai operate segment pharmaceutical division present divisional information million chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense roche finance report note roche group consolidate financial statement roche group pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination result division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group roche finance report roche group note roche group consolidate financial statement net operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment intangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue roche finance report note roche group consolidate financial statement roche group major customer total national wholesale distributor represent approximately group revenue national wholesale distributor mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenue pharmaceutical operating segment residual diagnostic segment supplementary revenue information revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim related sale estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment grosstonet sale reconciliation pharmaceutical division show table company diagnostic division similar reconciling item low amount pharmaceutical division sale grosstonet reconciliation million chf gross sale government regulatory mandatory price reduction contractual price reduction cash discount customer return reserve net sale government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan total usd billion equivalent chf billion usd billion equivalent chf billion contractual price reduction include rebate chargeback result contractual agreement primarily volumebase performancebase cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivable note sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability note provision sale return record balance sheet provision note revenue royalty operating income millions chf royalty income income outlicense agreement income disposal product total royalty operating income roche finance report roche group note roche group consolidate financial statement income outlicense agreement include upfront payment exclusive licence agreement dermira development worldwide commercialisation lebrikizumab atopic dermatitis potential indication income disposal product include divestment worldwide right bonviva bondronat exclude japan dilatrend kytril exclude japan income product disposal operating income include product divestment xenical net financial expense financing cost millions chf interest expense amortisation debt discount net gain loss debt derivative net gain loss redemption repurchase bond note discount unwind net interest cost define benefit plan total financing cost financial income expense millions chf net gain loss sale equity security net gain loss equity security derivative dividend income writedown impairment equity security net income equity security interest income net gain loss sale debt security net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss net financial income expense associate total financial income expense roche finance report note roche group consolidate financial statement roche group net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate decrease decrease mainly low proportion group profit relatively high local tax rate group average tax rate low proportion profit drive goodwill impairment group effective tax rate increase main driver increase goodwill impairment mention tax deductible impact intragroup transfer intangible right transitional effect change tax rate december change tax rate enact effective january change decrease federal tax rate group carry remeasurement defer tax position consequence net defer tax asset record balance sheet reduce chf million end result transitional expense chf million remain adjustment chf million record comprehensive income far relate temporary difference arise item record comprehensive income actuarial gainslosse pension plan roche finance report roche group note roche group consolidate financial statement group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development tax credit manufacturing deduction state tax impact tax unremitted earning utilisation previously unrecognise tax loss defer tax intragroup transfer transitional effect change tax rate prior year difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan availableforsale investment cash flow hedge currency translation foreign operation comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liabilitie current income tax liability include accrual uncertain tax position roche finance report note roche group consolidate financial statement roche group current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december defer taxis movement recognise net asset liability millions chf property define plant intangible benefit temporary equipment asset plan difference total year end december january charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december defer tax net asset temporary difference mainly relate accrue liability provision unrealise profit inventory defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable chf tax rate chf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste purpose financial statement total unremitted earning group regard permanently reinveste purpose financial statement chf billion december chf billion roche finance report roche group note roche group consolidate financial statement business combination acquisition mysugr gmbh june group acquire control interest mysugr gmbh mysugr private company base vienna austria mysugr develop lead mobile diabetes platform market group new digital health service diabetes care acquisition mysugr expand group lead position area diabete management mysugr report diagnostic operating segment diabetes care business total cash consideration eur million viewics inc november group acquire control interest viewic inc viewic privately own company base san jose california viewics software company focus laboratory business analytic solution acquisition viewic expand group lead position integrate core lab business analytic capability enable laboratory fast datadriven informed decision operation process viewic report diagnostic operating segment total consideration usd million usd million pay cash usd million defer consideration pay period date control usd million arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero usd million identifiable asset acquire liability assume set table amount mysugr viewic provisional base preliminary information valuation asset liability subject adjustment acquisition net asset acquire millions chf mysugr viewic total intangible asset product intangible use product intangible available use marketing intangible use cash cash equivalent defer tax liability net asset liability net identifiable asset fair value previously hold interest goodwill total consideration cash defer consideration contingent consideration total consideration fair value product intangible asset mysugr determine replacement cost method fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate mysugr viewic valuation perform independent valuer viewic account receivable comprise gross contractual amount chf million expect collectable date acquisition goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose roche finance report note roche group consolidate financial statement roche group group recognise financial gain chf million chf million respectively fair valuing interest mysugr interest viewic hold group prior transaction gain include financial income expense directly attributable transaction cost chf million report diagnostic operating segment general administration expense impact mysugr viewic acquisition result diagnostic division group material future acquisition ignyta inc december group announce enter merger agreement ignyta inc ignyta fully acquire ignyta price usd share allcash transaction correspond total transaction value usd billion fully dilute basis ignyta publicly own company base san diego california list nasdaq stock code rxdx closing transaction expect place half subject majority ignyta outstanding share tender group expiration termination waiting period hartscottrodino antitrust improvement act customary condition closing ignyta report pharmaceutical division acquisition group complete business combination cash flow business combination acquisition net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company transaction cost total net cash outflow roche finance report roche group note roche group consolidate financial statement global restructuring plan group initiate resource flexibility plan pharmaceutical division address future challenge include biosimilar competition area plan include biologic manufacturing commercial operation product development strategy group continue implementation major global restructuring plan initiate prior year notably strategic realignment pharmaceutical division manufacturing network programme address longterm strategy diagnostic division global restructuring plan cost incur millions chf diagnostic site consolidation plan total year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost include strategy plan diagnostic division diabetes care autonomy speed plan include pharmaceutical division strategic realignment manufacture network resource flexibility biologic manufacturing network include plan resource flexibility pharmaceutical division commercial operation global product developmentstrategy organisation pharmaceutical division research development strategic realignment outsourcing function diagnostic division strategy plan diagnostic division launch incur cost chf million mainly employee relate cost chf million related site closure employee spend small plan division chf million chf million include cost relate autonomy speed initiative diabetes care certain project roche finance report note roche group consolidate financial statement roche group site consolidation november pharmaceutical division announce strategic realignment manufacturing network include exit manufacture site clarecastle ireland legans spain segrate italy florence cost plan chf million chf million chf million noncash impairment accelerate depreciation property plant equipment chf million employeerelate provision reverse likely scenario segrate site change closure divestment divestment florence segrate legan site complete result total cost chf million include chf million accumulate currency translation loss consolidation transfer income statement note expect cost environmental remediation clarecastle site reassess result increase provision environmental remediation note plan include resource flexibility biologic manufacturing network result headcount reduction kaiseraugst site switzerland exit small molecule manufacturing site toluca mexico divestment nutley site complete second half result increase provision environmental remediation global restructuring plan total cost chf million major item chf million resource flexibility pharmaceutical division include global field force reduction notably europe remain chf million include plan outsource function share service centre external provider total cost chf million major item chf million pharmaceutical division research development strategic realignment chf million informatic mainly outsource function share service centre external provider remain minor plan total chf million global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost divestment product business gain loss divestment subsidiary gain loss divestment product business total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost roche finance report roche group note roche group consolidate financial statement global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche finance report note roche group consolidate financial statement roche group property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal divestment subsidiary transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment charge impairment charge property plant equipment mainly relate global restructuring plan note reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment roche finance report roche group note roche group consolidate financial statement divestment nutley site september group complete divestment nutley site total net consideration receive cash chf million genentech property purchase option exercise genentech enter master lease agreement mla slough ssf llc slough subsequently acquire health care property lease property adjacent genentechs south san francisco site develop slough development include total building construction complete time genentech fully occupy property property lease extension option november genentech exercise purchase option contain mla acquire building land december group record addition land building land improvement correspond liability cash outflow group reclassify finance lease accounting balance previously apply building november close payment usd million final closing payment usd million july record current liability note leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease chf million chf million net book value asset chf million chf million carrying value leasing obligation chf million chf million report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum lease payment payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly property rental motor vehicle arrangement impose significant restriction group total operating lease rental expense chf million chf million operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method roche finance report note roche group consolidate financial statement roche group finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year total unearned finance income na na unguaranteed residual value na na net investment lease accumulate allowance uncollectible minimum lease payment chf million chf million operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion lease party operate lease future minimum lease receipt noncancellable lease millions chf year year year total minimum receipt capital commitment group noncancellable capital commitment purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group note roche group consolidated financial statement goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical foundation medicine chugai total pharmaceutical division diabetes care centralise point care solution molecular diagnostic tissue diagnostic sequence divisional goodwill total diagnostic division impairment charge impairment charge total chf million related charge chf million diagnostic division writeoff sequence business goodwill factor lead impairment decrease forecast cash flow relative previous year longterm forecast change assumption market penetration pricing reimbursement ii revise time market single molecule sequence technology addition impairment charge chf million record sequence business product intangible use acquire ariosa acquisition note charge chf million pharmaceutical division writeoff goodwill relate seragon acquisition decision stop development backup compound acquire impairment charge goodwill impairment charge chf million record pharmaceutical division writeoff goodwill anadys pharmaceuticals inc acquisition deem disposed roche finance report note roche group consolidate financial statement roche group impairment testing pharmaceutical division division operate segment cashgenerate unit test goodwill goodwill arise foundation medicine acquisition record monitor roche pharmaceutical level relate strategic development roche pharmaceutical cashgenerate unit strategic goodwill roche pharmaceutical recoverable impairment testing high value use fair value cost disposal chugai foundation medicine fair value cost disposal determined reference publicly quote share price chugai foundation medicine share diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division goodwill arise viewic acquisition monitor divisional level recoverable impairment testing base value use value use calculate discount expect cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate group weight average cost capital cash generating unit integrate operation large part group derive capital asset pricing model data capital market include government twentyyear bond assess value use cash flow projection base recent longterm forecast approve management longterm forecast include management late estimate sale volume pricing production operating cost assume significant change organisation key assumption calculation period cash flow projection include longterm forecast terminal value growth rate discount rate key assumption value use calculation period terminal period terminal cash flow value discount rate cash flow value discount rate projection growth rate tax projection growth rate tax pharmaceutical division roche pharmaceutical year na year na diagnostic division sequence year year diagnostic business year year cashgenerating unit terminal value growth respective rate exceed longterm project growth rate relevant market year period cash flow projection reflect longterm nature development sequence business sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai foundation medicine decrease publicly quote share price result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable amount december roche finance report roche group note roche group consolidate financial statement intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group roche finance report note roche group consolidate financial statement roche group significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use intermune acquisition roche pharmaceutical year foundation medicine acquisition roche pharmaceutical year ariosa acquisition diagnostic year kapa acquisition diagnostic year cmi acquisition diagnostic year iquum acquisition diagnostic year product intangible available use biontech licence transaction roche pharmaceutical na geneweave acquisition diagnostic na genia acquisition diagnostic na technology intangible use dutalys acquisition roche pharmaceutical year classification intangible asset amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product roche finance report roche group note roche group consolidate financial statement intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lowerthananticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total chf million record relate charge chf million partial impairment esbriet product intangible use acquire intermune acquisition asset concern write estimate recoverable value chf million main factor lead decrease forecast cash flow relative previous year longterm forecast reduction sale expectation intangible asset continue amortise remain estimate useful life year charge chf million launch competitor product compound acquire trophos acquisition asset concern amortise write estimate recoverable value chf million charge chf million decision stop development compound alliance partner follow assessment clinical nonclinical datum asset concern amortise fully write charge chf million decision stop development compound acquire dutaly acquisition asset concern amortise fully write charge chf million decision stop development compound acquire santaris acquisition follow clinical datum assessment asset concern amortise fully write charge chf million decision stop development compound different alliance partner asset concern amortise fully write charge chf million follow clinical datum assessment asset concern amortise fully write diagnostic division impairment charge total chf million record relate charge chf million partial impairment molecular diagnostic product intangible available use acquire geneweave acquisition factor lead partial impairment decrease forecast cash flow follow change timeline future product development pricing penetration rate update market size assumption asset concern amortise write estimate recoverable value chf million charge chf million partial impairment sequence business product intangible use acquire ariosa acquisition factor leading impairment decrease forecast cash flow follow revise assumption price penetration rate market dynamic asset concern amortise write estimate recoverable value chf million impairment charge pharmaceutical division impairment charge total chf million record relate decision stop development compound acquire seragon acquisition follow clinical datum assessment chf million asset concern amortise fully write delay development compound acquire trophos acquisition follow regulatory feedback chf million asset concern amortise write estimate recoverable value chf million portfolio reassessment compound chf million asset concern amortise fully write clinical datum assessment development project different alliance partner chf million asset concern amortise fully write decision stop development compound chf million asset concern amortise fully write diagnostic division impairment charge total chf million record related sequence product intangible use chf million result decision stop product development commercialisation licence agreement alliance partner asset concern amortise fully write tissue diagnostic product intangible use chf million result strategic portfolio reassessment asset concern amortise fully write roche finance report note roche group consolidate financial statement roche group potential commitment alliance collaboration purchase agreement year group party inlicense similar arrangement alliance partner intangible asset purchase agreement party arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment payment year set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration purchase payment december millions chf pharmaceutical diagnostic group year year year total inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total chf billion chf billion inventory writedown year result expense chf million chf million account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance withhold settlement total account receivable roche finance report roche group note roche group consolidate financial statement allowance doubtful account movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense record marketing distribution cost total chf million expense chf million marketable security marketable security millions chf availableforsale financial asset equity security debt security money market instrument time account month investment total marketable security marketable security hold fund management purpose primarily denominate swiss franc dollar euro money market instrument contract mature year december debt security contract maturity million chf year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent roche finance report note roche group consolidate financial statement roche group noncurrent asset noncurrent asset million chf availableforsale investment hold fair value availableforsale investment hold cost loan receivable longterm trade receivable restrict cash receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset availableforsale investment mainly equity investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably current asset current asset millions chf accrue interest income derivative financial instrument restrict cash cash collateral receivables receivables total financial current asset prepaid expense accrue income taxis recoverable asset total nonfinancial current asset total current asset receivables mainly relate royalty licensing income receivables roche finance report roche group note roche group consolidated financial statement account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability mainly relate accrued employee benefit include genentech property purchase option exercise obligation july note current liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument cash collateral payable accrue chargeback allowance separately payable accrue royalty commission accrue liability total current liability december accrue liability include chf million shortterm genentech property purchase option exercise obligation july note roche finance report note roche group consolidate financial statement roche group provision contingent liability provision movement recognise liability millions chf contingent legal environmental restructure consideration provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration currency translation effect december current noncurrent december expect outflow resource year year year year december group revise presentation provision contingent consideration provision present separately employee provision include provision comparative period information restate accordingly chf million provision utilise chf million chf million chf million include cash flow operating activity chf million chf million include cash flow business combination payment deferred contingent consideration arrangement note roche finance report roche group note roche group consolidate financial statement legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict regular review litigation matter management reassess provision record certain litigation matter base development litigation notably accutane case provision previously hold release result income chf million major element legal expense net income chf million net expense chf million detail major legal case outstanding disclose environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate site nutley new jersey divest september estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago estimate remediation cost manufacturing site clarecastle ireland expect cost environmental remediation clarecastle site reassess accordingly environmental provision increase chf million major element environmental expense net expense chf million net expense chf million group procedure environmental protection include annual report page include action take group regard climate change notably group commitment reduce greenhouse gas emission restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate strategic realignment manufacturing network include exit manufacturing site resource flexibility plan address future challenge include biosimilar competition research development strategic alignment outsourcing function share service centre external provider note contingent consideration provision group party certain contingent consideration arrangement arise business combination significant provision discount average discount rate time value money material additional detail measurement main movement provision total potential payment arrangement provide note roche finance report note roche group consolidate financial statement roche group provision provision relate item show table exception employee provision time cash outflow nature uncertain provision millions chf employee provision sale return item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note pharmaceutical legal case december provision legal case pharmaceutical division chf million chf million provision record case settled mainly relate matter list accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation mdl district court middle district florida tampa division august mdl closed pendency mdl district court grant summary judgment favour hlr federal ibd case proceed affirm court appeal eleventh circuit action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december case appeal usd million jury new jersey superior court rule favour plaintiff subsequently verdict reverse favour hlr january new jersey supreme court reinstate case remand appellate division consideration issue appellate division rule favour hlr reverse verdict remand new trial plaintiff file petition review supreme court remain pende february superior court new jersey law division atlantic county hold eightday evidentiary hearing plaintiff expert testify accutane cause crohns disease february superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss prejudice agreedupon list crohns disease case subject superior court february order july new jersey appellate division reverse order exclude plaintiff expert testify accutane cause crohns disease reinstate dismiss case find trial court wrongfully bar plaintiff expert witness hlr file petition review new jersey supreme court grant december oral argument expect roche finance report roche group note roche group consolidated financial statement superior court enter order grant summary judgment dismiss case file new jersey resident basis drug label adequate matter law july superior court grant hlrs motion summary judgment adequacy label post ingestion case jurisdiction superior court apply new jersey law jurisdiction grant hlrs motion dismiss approximately case alternative superior court apply home state law grant summary judgment jurisdiction deny jurisdiction resulted case dismiss july new jersey appellate division affirm dismissal case reinstate judgment case base strength hlrs warning hlr dismiss plaintiff file petition review new jersey supreme court grant december oral argument expect january october superior court enter order grant summary judgment dismiss case failure prove accutane proximately cause ulcerative colitis plaintiff appeal decision february march superior court new jersey law division atlantic county hold evidentiary hearing plaintiff expert testify accutane cause ulcerative colitis april superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss ulcerative colitis case subject superior court april order plaintiff appeal decision december hlr defend approximately action involve approximately plaintiff bring state court personal injury allegedly result use accutane approximately case appeal case survive appeal additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim base development litigation provision previously hold release avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche strongly disagree verdict tar appeal consiglio di stato italian ministry health notify roche spa intention seek damage relate matter july roche pay eur million fine protest avoid additional penalty fee record expense general administration fine relate interest reimburse roche win case january european court justice render decision question refer european court justice consiglio di stato principle define decision consiglio di stato render final verdict case outcome matter determined time pdl inhibitor litigation july bristolmyers squibb co bms file lawsuit genentech delaware bms allege genentech sale tecentriq infringe patent bms seek judgment favour find wilfulness monetary damage october genentech file answer counterclaim seek declaratory judgment invalidity patent outcome matter determined time average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey hlr rli vigorously defend trial date set outcome matter determined time rituxan arbitration october genentech biogen idec inc file complaint california sanofiaventis deutschland gmbh sanofiaventis llc sanofiaventis inc sanofi seek declaratory judgment certain genentech product include rituxan infringe sanofis patent nos patent invalid sanofi allege rituxan genentech product infringe certain claim patent march district court rule matter law genentech biogen idec infringe assert patent claim sanofi appeal court noninfringement rule appellate court affirm district court judgment patent infringement roche finance report note roche group consolidate financial statement roche group addition october sanofi affiliate hoechst gmbh hoechst file icc international court arbitration paris request arbitration genentech relate terminate patentlicence agreement hoechst predecessor genentech pertain abovementione patent relate patent outside hoechst seek payment patent licence royalty sale certain genentech product include rituxan damage breach contract relief arbitral award september february arbitrator find genentech liable hoechst patentlicence royalty rituxan award royalty interest hoechst seek february group record royalty expense chf million net assume reimbursement portion group obligation copromotion partner hoechst initiate proceeding france germany seek enforce arbitral awards october genentech pay award royalty interest hoechst protest genentech seek annulment arbitral award proceeding initiate court appeal paris hearing proceeding june september paris court appeal stay annulment proceeding seek guidance eu court justice specific legal question raise genentech relate arbitral award noncompliance eu competition law november hoechst file notice appeal french supreme court seek review paris court appeal decision seek guidance eu court justice november french supreme court deny hoechst challenge decision paris court appeal refer specific legal question eu court justice july eu court justice issue opinion case find licensee freely terminate licence licence anticompetitive september paris court appeal issue decision dismiss appeal rule favour hoechst expect matter finally conclude quarter addition matter list currently provision record potential future obligation confirm occurrence nonoccurrence uncertain future event obligation measure sufficient reliability boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action dismiss case canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time ema investigation october european medicines agency ema announce start infringement procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine november ema announce result pharmacovigilance risk assessment committee assessment roche medicine ema find impact benefitrisk balance roche medicine confirm benefitrisk profile base available safety information ema health authority confirm medicine remain authorised change treatment advice patient healthcare professional corrective preventative action result inspection implement reinspection authority november lead certain finding roche address accordingly april ema issue report european commission summarise emas findings relation investigation july european commission issue notification ema return case file ema new period inquiry july ema announce conclude second inquiry send july final update report european commission december european commission announce closed infringement procedure impose penalty matter conclude hemlibra emicizumab litigation baxalta inc baxalta subsidiary shire plc file patent infringement declaratory judgment patent infringement suit district court district delaware allege genentech inc chugai pharmaceutical co ltd currently imminently manufacture use sell offer sale import hemlibra emicizumab infringe baxalta patent baxalta seek judgment infringement injunctive monetary relief attorney fee cost expense genentech serve complaint genentech response counterclaim complaint file june june chugai waive service september chugai file motion dismiss complaint lack personal jurisdiction november food drug administration fda approve hemlibra emicizumab haemophilia inhibitor use december baxalta file motion preliminary injunction seek prevent genentech marketing selling hemlibra patient exclude inhibitor patient treat exclude inhibitor patient serve exist bypass treatment receive prophylactic bypass treatment outcome matter determine time roche finance report roche group note roche group consolidate financial statement security litigation june class action file united states district court district new jersey roche holding ltd current officer lawsuit bring claim federal security law connection group public disclosure particular respect matter relate roche drug herceptin perjeta substantially similar lawsuit follow group vigorously defend matter outcome matter determined time arbitration chugai medical research council lifearc medical research council technology claimant request arbitration chugai pharmaceutical co ltd arbitrator appoint august sum seek chugai allege breach obligation collaboration agreement date august connection development humanise antihuman il receptor monoclonal antibody actemra claim chugai oblige pay royalty claimants pursuant collaboration agreement chugai consider claim merit chugai vigorously defend arbitration outcome matter determine time debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt change finance cash flow net gain loss redemption repurchase bond note amortisation debt discount financing cost business combination net foreign currency transaction gain loss currency translation effect change foreign exchange rate change fair value hedge instrument change december bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche finance report note roche group consolidate financial statement roche group bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollar note fix rate note september principal usd billion isin usbc note march principal usd billion isin usuam usas note september principal usd billion isin usba note september principal usd billion isin usbb na note january principal usd billion isin usbm note september principal usd billion isin usbe na note november principal usd billion isin usbj na note principal usd billion isin usbk na note january principal usd billion isin usbl na note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh na dollar note float rate note september principal usd billion isin usbd na note september principal usd billion isin usaz na euro medium term note programme fix rate note march principal eur billion isin xs note june principal eur billion isin xs na note march principal usd billion isin xs note march principal eur billion outstanding eur billion isin xs note february principal eur billion isin xs na note august principal gbp billion outstanding gbp billion isin xs na note february principal eur billion isin xs na swiss franc bond fix rate bond march principal chf billion isin ch na bond september principal chf billion isin ch bond september principal chf billion isin ch na bond september principal chf billion isin ch bond september principal chf billion isin ch bond march principal chf billion isin ch na genentech senior note senior note july principal usd billion outstanding usd billion isin usac na total bond note roche finance report roche group note roche group consolidate financial statement bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note march group complete offer chf billion fix rate bond issue tranche chf million bond zero coupon mature september chf million bond coupon mature september chf million bond coupon mature march bond list swiss exchange group receive chf million aggregate net proceed issuance sale fix rate bond issuance bond note february group issue eur million fix rate note coupon euro medium term note programme note mature february list luxembourg stock exchange group receive chf million aggregate net proceed issuance sale fix note march group complete offer usd billion fix rate note coupon note mature group receive chf million aggregate net proceed issuance sale fix note october group complete offer usd million usd million fix rate note coupon respectively note mature january january respectively group receive chf million aggregate net proceed issuance sale fix note roche finance report note roche group consolidate financial statement roche group redemption repurchase bond note redemption swiss franc bond date march group redeem fix rate bond principal chf billion cash outflow chf million plus accrue interest effective interest rate bond redemption dollar note date september group redeem fix rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note date september group redeem float rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note redemption pound sterling note november group complete tender offer repurchase gbp million fix rate note august cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note redemption euro note november group complete tender offer repurchase eur million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note additional chf million gain recognise net gain loss redemption repurchase bond note come termination crosscurrency swap hedge tender portion euro note redemption repurchase bond note redemption dollar note december group resolve exercise option early partial redemption fix rate note march march group redeem outstanding principal usd million equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow chf million plus accrue interest december group revise carrying value note account change amount timing estimate cash flow result increase carry value usd million chf million record financing cost loss redemption additional chf million loss record redemption effective interest rate note june group resolve exercise option early partial redemption fix rate note march august group redeem outstanding principal usd million equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow chf million plus accrue interest loss redemption chf million effective interest rate note december group complete tender offer repurchase usd million fix rate note march cash outflow chf million plus accrue interest loss repurchase chf million effective interest rate note redemption euro note date march group redeem fix rate note principal eur billion cash outflow chf million plus accrue interest effective interest rate note roche finance report roche group note roche group consolidate financial statement cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf euro medium term note programme euro note dollar note swiss franc bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf euro medium term note programme pound sterling note euro medium term note programme euro note dollar note swiss franc bond total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue usd billion unsecured commercial paper note guarantee roche holding ltd total commit credit line available backstop support commercial paper program usd billion december maturity note program exceed day date issuance december unsecured commercial paper note principal usd billion average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency average interest rate december amount outstanding chf million chf million year roche finance report note roche group consolidate financial statement roche group equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense roche finance report roche group note roche group consolidate financial statement change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce chf billion chf billion allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report note roche group consolidate financial statement roche group share capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value chf precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis hold ag basel own participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security approve result total distribution shareholder chf million subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security total equity instrument record equity original purchase cost december fair value share chf million fair value nonvoting equity security chf billion equity instrument hold group potential conversion obligation arise group equity compensation plan note reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc roche finance report roche group note roche group consolidated financial statement subsidiary associate chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai roche finance report note roche group consolidate financial statement roche group licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnologybase drug discovery foundation medicine april group acquire control interest foundation medicine inc fmi publicly own company base cambridge massachusetts enter investor right agreement research development collaboration agreement commercial collaboration agreement fmi fully consolidate subsidiary group base group interest fmi december roche relationship fmi found agreement common stock fmi publicly trade list nasdaq stock code fmi fmi prepare financial statement accordance gaap file quarterly basis sec certain consolidation entry difference fmis standalone gaap result result fmi consolidated roche group accordance ifrs dividend dividend distribute party hold fmi share associates june group acquire interest senseonic hold inc senseonic publicly own company base germantown maryland result group interest senseonic investment assess treat associate group group interest senseonic december common stock senseonic publicly trade list new york stock exchange nysemkt stock code sen senseonic prepare financial statement accordance gaap file quarterly basis sec group account senseonic equity method base senseonic financial statement publicly available group share senseonic result loss chf million include financial income expense note carry value group share senseonic net asset december asset chf million include noncurrent asset note divestment subsidiary february group sell wholly own subsidiary roche carolina inc florence party previously announce pharmaceutical division strategic realignment manufacture network total consideration receive usd million cash total loss divestment chf million report global restructuring cost roche pharmaceutical operating segment include general administration roche finance report roche group note roche group consolidate financial statement september group sell wholly own subsidiary segrate site italy party previously announce pharmaceutical division strategic realignment manufacture network total consideration eur million eur million receive remain eur million receive total loss divestment chf million report global restructuring cost roche pharmaceutical operating segment include general administration total gain loss divestment show table gain loss divestment subsidiary millions chf consideration property plant equipment net asset liabilitie currency translation foreign operation transfer income statement total net asset dispose provision accrual residual obligation retain group gain loss divestment subsidiary noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income business combination dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest roche finance report note roche group consolidate financial statement roche group employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan chf million chf million asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan roche k saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation roche finance report roche group note roche group consolidate financial statement pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility operating income chf million record past service cost change group pension plan switzerland announce june represent impact adjustment pension liability plan change chf million record pharmaceutical division chf million diagnostic division chf million corporate past service income record general administration adjustment pension plan switzerland group payment chf million pension fund pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan underfunding normally remedie additional company contribution payment group usd million usd million decrease payment compare additional contribution benefit low insurance fee pension benefit guaranty corporation government agency oversee occupational pension scheme group enter annuity buyout agreement insurance company pay usd million plan asset settle define benefit obligation retire employee lead settlement loss usd million pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contributionbase minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs financial statement uk pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan group payment eur million pension fund ireland relation restructuring manufacturing site clarecastle ireland measure take group enter annuity buyout agreement insurance company pay eur million plan asset settle define benefit obligation retire employee addition transfer value payment eur million plan asset deferred employee settle define benefit obligation group record settlement loss eur million transaction postemployment benefit opeb plan represent approximately group define benefit obligation consist postemployment healthcare life insurance scheme mainly plan mainly unfunde andor contributory employee group reimburse retire employee directly financial resource group major opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund opeb plan roche finance report note roche group consolidate financial statement roche group define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation ifrs funding status fund define benefit plan improve reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liabilitie roche finance report roche group note roche group consolidated financial statement plan asset responsibility investment strategy fund plan senior governance body board trustee assetliability study perform regularly major pension plan study examine obligation postemployment benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset gain chf million gain chf million recognition plan asset limit present value economic benefit available refund plan reduction future contribution plan define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset remeasurement plan asset currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property mainly private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value chf million chf million debt instrument issue group fair value chf million chf million roche finance report note roche group consolidate financial statement roche group define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee uk join group define contribution plan new employee germany join contributionbase plan minimum guarantee result proportion define benefit obligation relate closed plan expect decrease future define benefit pension plan switzerland final benefit contributionbase minimum guarantee remain open new employee define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year roche finance report roche group note roche group consolidate financial statement actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour average life expectancy assume individual age follow define benefit plan average life expectancy age major scheme year male female country mortality table switzerland bvg projected cmi model united states rp project mp germany heubeck table g mortality assumption pension plan switzerland base bvg apply continuous mortality investigation cmi model longterm rate longevity improvement financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase generally link expected inflation rate funding status plan expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation roche finance report note roche group consolidate financial statement roche group define benefit plan sensitivity define benefit obligation actuarial assumption millions chf increase decrease define benefit obligation year increase life expectancy discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately chf million include estimate chf million additional contribution relate define benefit plan benefit pay unfunded plan estimate approximately chf million relate german define benefit plan roche finance report roche group note roche group consolidate financial statement equity compensation plan group operate equity compensation plan include separate plan chugai foundation medicine ifrs share base payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai foundation medicine plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai foundation medicine plan exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive non vote equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche finance report note roche group consolidate financial statement roche group roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance condition currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche performance share plan group offer future share nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award programme currently operate annual threeyear cycle roche performance share plan psp include value adjustment equivalent sum shareholder distribution group vest period attributable number share nonvoting equity security individual award grant share nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero share non vote equity security value adjustment depend achievement performance target roche finance report roche group note roche group consolidate financial statement roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equity settle award sevenyear duration vest phase basis year roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date roche finance report note roche group consolidate financial statement roche group fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche roche roche stocksettle stock restrict performance roche appreciation right stock unit plan share plan option plan progressively cliff vest cliff vest progressively vest period year year year year contractual life year na na year number grant year thousand weight average fair value chf model binomial market price monte carlo b binomial input option pricing model share price grant date chf exercise price chf expect volatility c na na expect dividend yield na na early exercise factor na na expect exit rate na na fair value roche rsus equivalent share price date grant b input parameter covariance matrix roche individual company peer group base threeyear history riskfree interest rate minus valuation take account define rank performance structure determine payout plan c volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf roche finance report roche group note roche group consolidate financial statement dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic division calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown inventory fair value adjustment net gain loss disposal product adjustment cash generate operation roche finance report note roche group consolidate financial statement roche group cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder increase decrease dividend payable dividend withholding tax total liability arise financing activity movement carry value recognise asset liability millions chf cash flow noncash change foreign outflow financing business fair value exchange january inflow cost combination rate december debt interest payable derivative financial instrument net cash collateral receivables payable net total debt interest payable derivative financial instrument net cash collateral receivables payable net total roche finance report roche group note roche group consolidate financial statement significant noncash transaction significant noncash transaction contingent consideration arrangement arise business combination note risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral longterm forecasting controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai foundation medicine appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai foundation medicine credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset account receivable december group trade receivables chf billion chf billion subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount december group combine trade receivable balance national wholesale distributor mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold trade receivables roche finance report note roche group consolidate financial statement roche group financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable chf billion chf billion public private customer country group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total age account receivable impair show table age account receivable impair millions chf overdue impair overdue month overdue month overdue month overdue month overdue year total account receivable cash marketable security december group cash marketable security chf billion chf billion subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution rate analysis cash fix income marketable security market value chf total chf total aaa range aa range range bbb range bbb range unrated total roche finance report roche group note roche group consolidate financial statement master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss availableforsale financial asset amount chf million chf million liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total chf billion chf billion chf billion serve backstop line commercial paper program remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carry value total year year year year year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability takeorpay commitments group enter contract manufacturing agreement company develop manufacturing capacity flexibility mainly pharmaceutical division future minimum takeorpay commitment agreement total potential commitment group chf billion december chf billion roche finance report note roche group consolidate financial statement roche group market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remain largely stable foreign exchange component decrease favourable exposure mix price component arise mainly movement equity security price remain largely stable foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument primary objective group interest rate management protect net interest result group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure roche finance report roche group note roche group consolidate financial statement price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai foundation medicine note chugai foundation medicine public company objective policy process manage capital determine local management roche finance report note roche group consolidate financial statement roche group financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf fair value total available hedge fair value loan financial carry forsale instrument designate receivables liability value fair value year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche finance report roche group note roche group consolidate financial statement fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date availableforsale investment base valuation model derive recently publish observable financial price group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year roche finance report note roche group consolidate financial statement roche group level fair value detail determination level fair value measurement set contingent consideration arrangement millions chf january arise business combination utilise settlement total unrealised gain loss include income statement unused amount reverse additional create discount unwind include financing cost total gain loss include comprehensive income currency translation effect december contingent consideration provision decrease mainly reversal provision payment milestone chf million income net mainly reversal remain provision relate seragon acquisition partial reversal provision mainly relate dutalys trophos acquisition payment chf million milestone relate genia cmi ariosa santaris acquisition contingent consideration arrangement group party certain contingent consideration arrangement arise business combination fair value determine consider expect payment discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate higher riskadjuste discount rate low december total potential payment contingent consideration arrangement chf billion chf billion follow potential payment contingent consideration arrangement millions chf acquisition year acquire operating segment trophos roche pharmaceutical dutalys roche pharmaceutical santaris roche pharmaceutical seragon roche pharmaceutical geneweave diagnostic genia diagnostic ariosa diagnostic cmi diagnostic diagnostic december derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement roche finance report roche group note roche group consolidate financial statement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net collateral arrangement november group complete tender offer repurchase eur million fix rate note march result hedge terminate cash receive group counterparty movement cash collateral receivable accrue liability millions chf january net cash deliver group fair value currency translation effect december hedge accounting december group follow cash flow hedge fair value hedge designate qualifying hedge relationship cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro december instrument record net fair value liability chf million chf million ineffective portion chugai enter foreign exchange forward contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset chf million fair value asset chf million ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow roche finance report note roche group consolidate financial statement roche group undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument december instrument record fair value liability chf million chf million fair value asset chf million chf million loss chf million record interest rate swap loss chf million fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument net investment hedge group net investment hedge relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool mr andr hoffmann dr andreas oeri members board director roche holding ltd mr hoffmann receive remuneration totalling chf chf dr oeri receive remuneration totalling chf chf transaction group individual member shareholder group exception dr jrg duschmal work postdoc roche subsidiary associate list group subsidiary associate include note list exclude subsidiary chugai fmi material company notably company inactive dormant liquidation transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate roche finance report roche group note roche group consolidate financial statement key management personnel total remuneration key management personnel chf million chf million member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee dr franz members corporate executive committee cec roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member cec members cec participate certain equity compensation plan describe term vest condition fair value award disclose note new member cec include table calendar year join cec similarly member cec retire way year include calendar year leave cec remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plans board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include remuneration report include annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date roche finance report note roche group consolidate financial statement roche group equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan contribution pay member corporate executive committee millions chf roche connect transaction member board director corporate executive committee pension totalling chf million pay group corporate executive committee member chf million define benefit plan transaction group define benefit plan employee group describe note list subsidiary associate follow list group subsidiary associate exclude subsidiary chugai fmi material company notably company inactive dormant liquidation list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million united states foundation medicine inc cambridge usd stock exchange nasdaq stock code fmi isin market capitalisation usd million united states senseonics holdings inc germantown usd stock exchange new york stock exchange nysemkt stock code sen isin usu market capitalisation usd million roche finance report roche group note roche group consolidated financial statement nonliste company share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ar roche diabetes care argentina sa tigre ar vanguardia en productos farmacuticos vanprofarma sa buenos aire ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited north ryde aud roche product pty limited dee aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk usd belgium nv roche sa brussels eur roche diagnostic belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche product limit hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad syntex pharmaceuticals international limited hamilton usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai ltd shanghai usd roche diagnostic suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai ien pharma co ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostic hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic producto roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostic egypt trading sae giza egp el salvador productos roche el salvador sa de cv san salvador svc estonia roche eesti tallinn eur finland roche diagnostic oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur trophos sa marseille eur georgia roche georgia llc tbilisi gel roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city millions germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabete care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche diagnostic solution gmbh berlin eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate service mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur signature diagnostic gmbh potsdam eur ghana roche product ghana limit accra ghs greece roche hellas sa athens eur roche diagnostic hellas sa athens eur guatemala producto roche guatemala sociedad annima guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostic india private limited mumbai inr roche product india private limited mumbai inr viewics india private limited pune inr indonesia pt roche indonesia jakarta idr iran roche par co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd hod hasharon il italy roche diabetes care italy spa monza eur roche diagnostic spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostic kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur macedonia roche makedonija dooel skopje eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr roche services asia pacific sdn bhd kuala lumpur myr syntex pharmaceutical sdn bhd kuala lumpur myr mauritius roche products mauritius ltd quatre borne mur mexico producto roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherland roche diabete care nederland bv almere eur roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions panama producto roche panama sa panama city pab producto roche interamericana sa prisa panama city usd peru producto roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diabete care rus moscow rub limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub saudi arabia roche product saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystem pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche product proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain emminens healthcare service sl madrid eur roche diabetes care spain sl sant cugat del valls eur roche diagnostic sl sant cugat del valls eur roche farma sa madrid eur sri lanka roche product colombo private limited colombo lkr sweden roche ab solna sek roche diagnostic scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabete care switzerland ltd rotkreuz chf roche diabetes care ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim sirketi istanbul try roche diagnostic turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city millions united arab emirate roche diabetes care middle east fzco dubai ae roche diagnostic middle east fzco dubai ae roche pharmaceutical middle east fzco dubai ae united kingdom intermune holding limit welwyn garden city gbp intermune uk limited welwyn garden city gbp kapa biosystems ltd london gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states adheron therapeutics inc wilmington usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapoli usd forsight vision inc south san francisco usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd genia technologies inc santa clara usd hlr consumer health inc little fall usd hoffmannla roche inc little falls usd igen international inc pleasanton usd igen ls llc pleasanton usd intermune inc south san francisco usd iquum inc marlborough usd kapa biosystem inc wilmington usd memory pharmaceutical corp little falls usd mysugr inc encinitas usd roche diabetes care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche health solutions inc indianapoli usd roche holdings inc south san francisco usd roche laboratory inc little fall usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequence solutions inc pleasanton usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc san jose usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital local currency unit roche finance report roche group note roche group consolidate financial statement significant accounting policy consolidation policy subsidiary company group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform single transaction split separately identifiable component reflect substance transaction necessary conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction roche finance report note roche group consolidate financial statement roche group cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase iv cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost roche finance report roche group note roche group consolidate financial statement pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur roche finance report note roche group consolidate financial statement roche group lease group lessee finance lease exist substantially risk reward ownership transfer group finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period lease group lessor certain asset mainly diagnostic instrument lease party finance operating lease arrangement finance lease asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method operating lease asset report property plant equipment lease income operating lease recognise lease term straightline basis business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value available use intangible asset amortise straight line basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost disposal value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciation amortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal roche finance report roche group note roche group consolidated financial statement impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cash generating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process intermediate include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise marketing distribution expenses trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available roche finance report note roche group consolidate financial statement roche group financial instrument financial instrument classify follow category disclose note availableforsale nonderivative financial asset designate classified financial asset category availableforsale asset initially record subsequently carry fair value change fair value record comprehensive income impairment interest foreign exchange component investment derecognise cumulative gain loss equity reclassify financial income expense availableforsale asset mainly comprise marketable security fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense fair value designate nonderivative financial instrument designate fair value profit loss initial recognition designate fair value instrument initially record subsequently carry fair value change fair value record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest rate method impairment loss loan receivables mainly comprise account receivable cash cash equivalent financial liability nonderivative financial liability financial liability initially record fair value subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire impairment financial asset financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity security market value original cost market value original cost sustain sixmonth period consider impaired financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income roche finance report roche group note roche group consolidated financial statement hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future tax liability uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan roche finance report note roche group consolidate financial statement roche group change accounting policy group implement minor amendment exist standard interpretation material impact group overall result financial position future new revise standard group assess expect impact new revise standard interpretation mandatory january group apply summarise base analysis date group anticipate material impact group overall result financial position furthermore restatement comparative result necessary new standard applied group assess new revise standard mandatory ifrs financial instrument group implement new standard effective january new standard replace ias financial instrument recognition measurement standard deal classification recognition measurement include impairment financial instrument introduce new hedge accounting model new standard result increase volume disclosure information annual financial statement classification measurement financial instrument currently marketable security classify availableforsale ia new standard equity security classify fair value profit loss debt security money market instrument fair value comprehensive income oci time account month amortise cost group elect classify certain strategic equity investment fair value oci additionally expect reclassification equity unrealised gain chf million net tax transfer fair value reserve retain earning january impairment financial assets january group change methodology assess impairment financial asset incur loss model ias expect credit loss model ifrs accordance transitional provision ifrs group restate prior period reassess impairment allowance new approach january result allowance doubtful account account receivable expect increase chf million loss allowance financial asset increase chf million recognise relate defer tax impact adjustment retain earning january hedge account new standard introduce new hedge accounting model require hedge accounting relationship base group risk management strategy objective discontinue relationship long qualify hedge accounting group apply revise hedge accounting guidance hedge relationship prospectively effect january hedge accounting relationship designate previous ias guidance expect continue valid hedge accounting relationship accordance ifrs presentational change result implement ifrs group number presentational change statement comprehensive income statement change equity note financial income expense note level fair value hedge accounting roche finance report roche group note roche group consolidate financial statement ifrs revenue contract customer group implement new standard effective january new standard replace ias revenue ias construction contract ifrs establishe comprehensive framework determine revenue recognise contain new requirement relate presentation core principle framework revenue recognise dependent transfer promise good service customer reflect consideration receive exchange good service objective standard provide fivestep approach revenue recognition include identify contract customer identify performance obligation determine transaction price allocate transaction price performance obligation recognise revenue performance obligation satisfied judgement need apply include make estimate assumption multipleelement contract identify performance obligation constrain estimate variable consideration allocate transaction price performance obligation lease component particularly diagnostic business outlicense agreement new standard result increase volume disclosure information annual financial statement change introduce standard relevant roche group new standard provide new requirement additional guidance relevant group notably follow area revenue licence intellectual property include salesbased royalty constrain estimate variable consideration development milestone provide material right receive additional good free charge certain patient access programme regard separate performance obligation involve variable consideration group anticipate material impact change new standard clarify allocate sale include treatment discount element multipleelement contract recognise sale element contract enter diagnostic division typically include obligation instrument include provide leasing arrangement reagent consumable service require use estimate assumption judgement apply guidance practice group anticipate material impact guidance outlicense contract pharmaceutical division enter obligation include commitment research latestage development regulatory approval comarketing manufacturing settle combination upfront payment milestone payment reimbursement service provide consider commitment single performance obligation separate one scope ifrs straightforward require judgement depend conclusion result revenue calculate inception recognise spread term long performance obligation answer new standard different currently new standard provide exemption salesbase royalty licence intellectual property continue recognise revenue underlie sale incur transition approach use practical expedient group apply retrospective method transition certain practical expedient permit standard transition notably relief restate contract began complete complete january provide disclosure requirement ifrs paragraph comparative period transaction price allocate remain performance obligation new standard include use practical expedient modify time amount revenue recognise restatement necessary presentational change result implement ifrs group presentational change income statement include subtotal revenue create new note revenue include increase volume require disclosure information ifrs lease group implement new standard effective january apply cumulative catchup method transition mean comparative result restate new standard apply new standard result increase volume disclosure information annual financial statement main impact new standard bring operating lease onbalance sheet group assess potential impact currently anticipate new standard result carry value lease asset increase approximately chf billion lease liability increase similar date implementation application new standard result currently report operating lease cost record interest expense give lease involve current low interest rate environment group currently expect effect material roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group statutory auditor report statutory auditor report general meeting roche holding ltd basel report audit consolidated financial statement opinion audit consolidated financial statement roche holding ltd subsidiary group comprise consolidated balance sheet december consolidated income statement consolidate statement comprehensive income consolidate statement change equity consolidate statement cash flow year end note consolidate financial statement include summary significant accounting policy opinion consolidated financial statement page true fair view consolidate financial position group december consolidated financial performance consolidated cash flow year end accordance international financial reporting standard ifrs comply swiss law basis opinion conduct audit accordance swiss law international standard auditing isa swiss auditing standard responsibility provision standard describe auditor responsibility audit consolidated financial statement section report independent group accordance provision swiss law requirement swiss audit profession iesba code ethic professional accountant fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter chargeback rebate sale return pharmaceutical business carrying value goodwill relate diagnostic division carry value productrelate intangible asset provision contingent liability respect litigation uncertain tax position key audit matter matter professional judgement significance audit consolidated financial statement current period matter address context audit consolidated financial statement form opinion thereon provide separate opinion matter roche finance report statutory auditor report roche group chargeback rebate sale return pharmaceuticals business key audit matter response group pharmaceutical business make sale audit procedure include test customer fall certain commercial group key control relate deduction governmentmandated contract purchase gross sale chargeback rebate sale reimbursement arrangement significant return include control accrual rate medicaid b drug discount program management calculation accrue liability group provide right return customer provision deduction account receivable certain product return period case extend year future arrangement sample basis obtain management calculation result deduction gross amount invoice arrive accrue liability provision account receivable revenue create obligation group provide deduction recalculate amount validate customer chargeback rebate reasonableness key assumption reference credit sale return estimate amount deduct internal external source include term gross sale record accrue liability rebate applicable contract government pricing information provision sale return deduction historical chargeback rebate historical sale account receivable chargeback estimate return level current trend base analyse exist contractual legislatively mandate obligation historical trend group consider accuracy management estimate experience previous year compare historical accrue liability provision accounts receivable deduction record management determine accrue liability actual settlement assess change deduction account receivable expect chargeback accrual rate estimate include rebate predominantly medicaid chf respond increase utilisation b drug million necessary december additionally discount program compare accrual rate provision sale return mainly relate product current chargeback rebate payment sale return near loss exclusivity chf million record trend december consider adequacy group revenue focus area arrangement recognition accounting policy include recognition complex establish appropriate yearend measurement deduction gross sale relate position require significant judgement estimation chargeback rebate sale return related management assumption require estimating disclosure provision sale return complicated give recent impending loss exclusivity group pharmaceutical product information chargeback rebate sale return pharmaceutical business refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note account receivable note current liability note provision contingent liability roche finance report roche group statutory auditor report carry value goodwill relate diagnostic division key audit matter response group goodwill chf million arise audit procedure include test past acquisition diagnostic division principally group key control surround carry value corangeboehringer mannheim ventana goodwill relate diagnostic division business sequence business area goodwill assess impairment reporting date audit goodwill include assess group additionally test annually impairment budgeting procedure forecast base integrity discount cash flow model impairment testing use projection future cash flow management prepare valuation challenge base recent longterm forecast approve robustness key assumption determine management include estimate sale volume price recoverable amount include identification allocation longterm forecast project year cgu forecast cash flow growth rate sequence business project discount rate base understand commercial year reflect long period require development prospect diagnostic business market technology product necessary grow operate business valuation specialist management need apply considerable judgement assist evaluate assumption methodology allocate goodwill appropriate business management particular relate assess future performance prospect discount rate compare relevant assumption cashgenerate unit cgu discount rate industry economic forecast addition identify apply certain business face uncertaintie technical analyse change assumption prior period commercial viability leadingedge nextgeneration assessment consistency assumption technology product develop perform comparison assumption publicly available datum perform retrospective focus area light judgement assessment accuracy management past estimation require history impairment record projection compare historical forecast actual result previous year amount headroom cgus forecast support carry value goodwill exceed usual period year case goodwill relate sequence business challenge management reason assessment management ability forecast cash flow long period reasonable accuracy review forecast relate value use sequence business impairment chf million record consider factor contribute impairment related event period consider continued use tenyear forecast period business development assess group disclosures sensitivity outcome impairment assessment change key assumption reflect risk inherent valuation goodwill information carry value goodwill relate diagnostic division refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note goodwill roche finance report statutory auditor report roche group carry value productrelate intangible asset key audit matter response group significant productrelate intangible asset audit procedure include test december chf million acquire group key control carry value product business combination inlicense arrangement relate intangible asset comprise product intangible use chf million amortise product intangible available audit productrelate intangible asset use use chf million amortise impairment include assess group process key control assessment carry productrelate intangible identify trigger event circumstance evidence asset impaired evidence asset impair challenge intangible asset available use robustness key assumption determine test impairment annually recoverable amount include forecast revenue useful life discount rate challenge base product intangible use chf million predominantly understand commercial prospect individual relate acquire product launch product relevant business area market key risk ability successfully commercialise operate valuation specialist product concern large single intangible asset assist evaluate assumption methodology arise acquisition intermune relate management relation discount rate esbriet chf million focus product assessment relation key input intangible use assess recoverability involve project pricing volume product project forecasting discount future cash flow share therapeutic area vitro diagnostic market inherently highly judgemental headroom compare relevant assumption industry forecast low key estimate assumption include revenue growth review analyst commentary retrospective timing impact loss exclusivity discount rate assessment accuracy previous projection development commercialisation compete compare management assumption external data product driver revenue growth include persistence available example case esbriet rate treatment rate market share consider high risk impairment perform sensitivity analysis individual intangible product intangible available use chf million asset impairment model assess level sensitivity represent inprocess research development key assumption focus work area asset inherent uncertainty research assess management allowance risk development process intangible asset available use particularly risk impairment impairment productrelate intangible available use assessment require management key assumption audit include assess reasonableness judgements clinical technical commercial management assumption probability viability new product accordingly focus obtain regulatory approval comparison industry audit work area risk include inability practice past history consideration group achieve successful trial result obtain require clinical internal governance approval process regulatory approval highly competitive business interview number senior research development environment therapeutic area group commercial personnel order understand challenge significant asset research development assumption information carry value productrelate intangible asset refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note intangible asset roche finance report roche group statutory auditor report provision contingent liability respect litigation key audit matter response pharmaceutical industry heavily regulate discuss status significant know actual increase inherent litigation risk normal course potential litigation inhouse legal counsel management business liability arise productspecific director knowledge matter general legal proceeding antitrust challenge decision rationale provision hold government investigation december decision record provision disclosure group hold provision chf million respect legal significant matter assess action give highly complex nature regulatory relevant historical recent judgment pass legal case management apply significant judgement court authority consider legal opinion obtain consider provide management external lawyer challenge basis potential exposure matter estimate provision record disclosure change substantially time new fact emerge group relevant obtain formal legal case progress confirmation group external lawyer focus area give number complexity assess group internal audit report magnitude potential exposure group compliance log report prepare management judgement necessary determine identify actual potential noncompliance law amount provide andor disclose regulation specific group business relate conduct business generally matter management conclude provision record consider adequacy completeness group disclosure relation contingent liability information provision contingent liability respect litigation refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note provision contingent liability roche finance report statutory auditor report roche group uncertain tax position key audit matter response group operate wide range different significant item challenge management tax jurisdiction world subject judgement eventual resolution national occasional challenge local tax authority include cross tax authority double taxation conflict pende tax border transfer pricing arrangement good service audits estimate tax exposure assistance finance transactionrelate tax matter connection local country tax specialist significant integration investment divestment uncertain tax position work include assessment licensing contract area particular focus include transfer thirdparty opinion use available pricing arrangement relate group past experience tax authority respective manufacturing supply chain jurisdiction additionally tax specialist expertise assess appropriateness key tax liability uncertain group assumption management conclude recognise accrual reflect management well estimate good estimate outcome outcome base fact know relevant jurisdiction group open tax transfer pricing audit approach include additional audit procedure matter tax authority range perform group level consider significant possible outcome broad december uncertain tax position particular transfer price apply group recognise current income tax liability good service intellectual property right chf million include accrual uncertain tax position focus area estimate amount tax receivable payable require significant level expertise judgement information uncertain tax position refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note income taxis roche finance report roche group statutory auditor report information annual report board director responsible information annual report information comprise information include annual report include consolidated financial statement standalone financial statement company remuneration report auditor report thereon opinion consolidated financial statement cover information annual report express form assurance conclusion thereon connection audit consolidated financial statement responsibility read information annual report consider information materially inconsistent consolidated financial statement knowledge obtain audit appears materially misstate base work perform conclude material misstatement information require report fact report regard responsibility board director consolidate financial statement board director responsible preparation consolidate financial statement true fair view accordance ifrs provision swiss law internal control board director determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement board director responsible assess group ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate group cease operation realistic alternative auditor responsibility audit consolidated financial statement objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law isa swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement audit accordance swiss law isa swiss auditing standard exercise professional judgment maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease continue go concern roche finance report statutory auditor report roche group evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement represent underlie transaction event manner achieve fair presentation obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidated financial statement responsible direction supervision performance group audit remain solely responsible audit opinion communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable relate safeguard matter communicate board director relevant committee determine matter significance audit consolidated financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag ian starkey marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report roche group independent reasonable assurance report internal control financial reporting independent reasonable assurance report internal control financial reporting board director roche holding ltd basel engage board director carry reasonable assurance engagement design implementation operating effectiveness system internal control financial reporting roche group place december management roche holding ltd assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso responsibility board director management board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting entitys internal control financial reporting process design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs entitys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate responsibility responsibility examine design implementation effectiveness company internal control financial reporting report thereon form independent reasonable assurance conclusion base evidence obtain conduct engagement accordance international standard assurance engagement isae assurance engagement audits review historical financial information issue international auditing assurance standard board standard require plan perform procedure obtain reasonable assurance effective internal control financial reporting maintain material respect procedure select depend judgement include assessment risk material misstatement design implementation effectiveness company internal control financial reporting examination include obtain understand internal control financial reporting testing evaluate design implementation operating effectiveness internal control base assess risk perform procedure consider necessary circumstance roche finance report independent reasonable assurance report internal control financial reporting roche group independence quality control firm apply international standard quality control accordingly maintain comprehensive system quality control include document policy procedure compliance ethical requirement professional standard applicable legal regulatory requirement comply independence ethical requirement code ethic professional accountant issue international ethic standard board accountant found fundamental principle integrity objectivity professional competence care confidentiality professional behaviour conclusion conclusion form basis subject matter outline report believe evidence obtain sufficient appropriate provide basis conclusion opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ag ian starkey marc ziegler license audit expert license audit expert basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group alternative performance measure financial information include financial review include certain alternative performance measure apm accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate apm instead consider alternative group consolidated financial result base ifrs apm comparable similarly title measure disclose company apm present financial review relate performance current year comparative period core result core result allow assessment group actual result define ifrs underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting impact accounting alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental case financial review exclude global issue outside healthcare sector group control exclude material treasury item major debt restructuring currently exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary information core result reconciliation million chf alliance normali global intangible business legal pension sation restruc amorti intangible combi environ plan global ecp tax ifrs ture sation impairment nation mental settlement issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal pension sation restruc amorti intangible combi environ plan global ecp tax ifrs ture sation impairment nation mental settlement issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report multiyear overview supplementary information roche group divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core ep basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share diluted chf free cash flow free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business operate free cash flow calculate base ifrs operating profit adjust certain cash item movement net work capital capital expenditure investment property plant equipment intangible asset operate free cash flow different cash flow operating activity define ias include capital expenditure responsibility divisional management exclude income taxis pay responsibility divisional management cash outflow define benefit plan allocate operate free cash flow base current service cost residual allocate treasury activity free cash flow calculate operate free cash flow adjust treasury activity taxis pay free cash flow different total cash flow define ia exclude dividend payment cash inflowsoutflow financing activity issuancerepayment debt purchasesale marketable security cash inflowsoutflow merger acquisition divestment roche finance report multiyear overview supplementary information roche group operate free cash flow free cash flow calculate show table additional commentary adjustment item give financial review operate free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia add income taxis pay deduct investment property plant equipment investment intangible asset disposal property plant equipment disposal intangible asset pension postemployment benefit add total payment define benefit plan deduct allocation payment operate free cash flow operating item operate free cash flow free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia deduct investment property plant equipment investment intangible asset disposal property plant equipment disposal intangible asset interest pay operating item treasury item free cash flow roche finance report roche group multiyear overview supplementary information supplementary information calculate divisional operate free cash flow show table divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda group use earning interest tax depreciation amortisation ebitda internal management report external communication opinion group management operate free cash flow give useful consistent measurement cash earning ebitda include noncash item provision allowance trade receivables inventory certain noncash entry arise acquisition accounting pension accounting convenience reader use ebitda provide table start point use core result exclude amortisation impairment goodwill intangible asset ebitda core result million chf pharmaceutical diagnostic corporate group ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report multiyear overview supplementary information roche group net operating asset net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment goodwill intangible asset net work capital longterm net operating asset minus provision calculation net operating asset disclose note annual financial statement show table net operating asset reconciliation millions chf taxation pharmaceutical diagnostic corporate treasury group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net operating asset net operating asset reconciliation millions chf taxation pharmaceutical diagnostic corporate treasury group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net operating asset net debt net debt monitor group overall short longterm liquidity net debt calculate sum total debt longterm shortterm marketable security cash cash equivalent net debt calculation include detail movement current year show table financial review roche finance report roche group multiyear overview supplementary information net working capital net working capital assess group efficiency utilise asset shortterm liquidity net trade work capital calculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net work capital net trade work capital calculation show table pharmaceutical division diagnostic division corporate financial review constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number foreign exchange gain loss exclude calculation cer growth rate earning share calculation country significant devaluation local currency current year simulation use average exchange rate current year instead prior year avoid cer growth rate artificially inflate roche finance report roche security roche group roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr sp index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july information table restate change ratio adr effective january change ratio adr effective january change ratio adr effective february roche finance report roche group roche security number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend c stock price share b open high low yearend stock price nonvoting equity security genussschein b open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy significant shareholder shareholder equity fulltime equivalent employee contingent liability board executive shareholding appropriation available earning statutory auditor report general meeting roche holding ltd basel roche finance report roche holding ltd basel financial statement financial statement balance sheet millions chf december december current asset cash cash equivalent marketable security account receivable group company shortterm loan group company current receivables total current asset noncurrent asset longterm loan group company investment total noncurrent asset total asset shortterm liability account payable group company interestbeare liability group company shortterm liability total shortterm liability longterm liability provision total longterm liability total liability shareholder equity share capital nonvoting equity security genussscheine pm pm legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year total shareholder equity total shareholder equity liability pm pro memoria nonvoting equity security nominal value roche finance report financial statement roche holding ltd basel income statement millions chf year end december income income investment dividend income financial income interest income loan group company income marketable security guarantee fee income group company income total income expense administration expense expense financial expense direct taxis total expense net income roche finance report roche holding ltd basel note financial statement note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report nd title swiss code obligation co prescribe law significant accounting principle apply describe company prepare consolidated financial statement accordance recognise accounting standard international financial reporting standard accordance co company decide forgo present additional information audit fee note cash flow statement valuation method translation foreign currency marketable security report low cost market value financial asset include investment report cost appropriate writedown equity instrument recognise cost deduct equity time purchase equity instrument sell gain loss recognise income statement asset liability denominate foreign currency translate swiss franc yearend rate exchange investment translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer investment direct indirect investment company list note roche group annual financial statement list exclude subsidiary chugai fmi material company notably company inactive dormant liquidation ownership interest equal voting right taxis direct taxis include corporate income capital taxis shareholder equity share capital previous year share capital amount chf million share capital consist bearer share nominal value chf include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate roche finance report note financial statement roche holding ltd basel equity instrument december company hold roche share company purchase roche share company sell roche share roche share sell average sale price chf share net gain chf million dividend income receive chf million company subsidiary meet definition requirement article b co hold equity instrument roche group annual financial statement entity mainly foundation include consolidation qualify subsidiary article b co movement recognise amount million chf legal voluntary reserve retain earning share retain free special available equity total capital earning reserve reserve earning instrument equity january net income dividend transaction equity instrument december net income dividend transaction equity instrument december net income dividend transaction equity instrument december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company roche finance report roche holding ltd basel note financial statement control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis hold ag basel participation fulltime equivalent employee annual average number fulltime equivalent employee exceed people board executive shareholding board director director mr andr hoffmann dr andreas oeri certain member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine ch franz hoffmann p baschera na na j bell j brown p bulcke hauser na na rp lifton e oeri b poussot schwan b c suessmuth dyckerhoff c c pr voser total include share hold shareholder group pool voting right b member corporate executive committee dr schwans shareholdings disclose table c jointly hold close relative close relative hauser hold nonvoting equity security genussscheine na e rp lifton hold roche american depositary receipt adr adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july roche finance report note financial statement roche holding ltd basel corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine sschwan rdiggelmann ahippe ga keller b doday wilbur total equity compensation award ssar rsus roche performance share plan b close relative dr keller hold roche share roche share december members corporate executive committee hold stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page ssar award hold december year issue total sschwan rdiggelmann ahippe ga keller doday wilbur total cec strike price chf expiry date mar mar mar mar mar mar feb december members corporate executive committee hold restrict stock unit rsus show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page rsus remuneration component corporate executive committee replace award correspond performance share plan psp award rsu award vest recipient year nonvoting equity security remain block year rsu award hold december year issue total sschwan na na rdiggelmann na na ahippe na na ga keller na na doday na na wilbur na na total cec na na roche finance report roche holding ltd basel note financial statement december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page award result zero nonvoting equity security share value adjustment depend achievement performance target discretion board director vest nonvoting equity security share remain block year end cycle performance target achieve accordingly participant receive originally target share total target number award outstanding performance cycle december show table roche performance share plan award hold december psp psp schwan r diggelmann hippe ga keller oday wilbur total cec allocation date feb feb information relate number value right option award grant employee roche group member board director corporate executive committee company disclose note note roche group annual financial statement roche finance report appropriation available earning roche holding ltd basel appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year total appropriation available earning carry forward account roche finance report roche holding ltd basel statutory auditor report statutory auditor report general meeting roche holding ltd basel report audit financial statement opinion audit financial statement roche holding ltd comprise balance sheet december income statement year end note financial statement include summary significant accounting policy opinion financial statement page year end december comply swiss law company article incorporation basis opinion conduct audit accordance swiss law swiss auditing standard responsibility provision standard describe auditor responsibility audit financial statement section report independent entity accordance provision swiss law requirement swiss audit profession fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion report key audit matter base circular federal audit oversight authority key audit matter matter professional judgement significance audit financial statement current period determine key audit matter communicate report responsibility board director financial statement board director responsible preparation financial statement accordance provision swiss law company article incorporation internal control board director determine necessary enable preparation financial statement free material misstatement fraud error prepare financial statement board director responsible assess entitys ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate entity cease operation realistic alternative auditor responsibility audit financial statement objective obtain reasonable assurance financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis financial statement roche finance report statutory auditor report roche holding ltd basel audit accordance swiss law swiss auditing standard exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure c onclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt entitys ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause entity cease continue go concern communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable relate safeguard matter communicate board director relevant committee determine matter significance audit financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ag ian starkey marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve roche finance report publish cautionary statement forwardlooke statement f hoffmannla roche ltd annual report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ orderdownload publication materially future reflect forwardlooke internet rochecompublication statement contain annual report email baselwarehouseservicesrochecom pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring product medium relation market fluctuation currency exchange rate general tel financial market condition uncertaintie discovery email rochemediarelationsrochecom development marketing new product new use exist product include limitation negative result clinical investor relation trial research project unexpected effect pipeline tel market product increase government pricing pressure email investorrelationsrochecom interruption production loss inability obtain adequate protection intellectual property right litigation corporate sustainability committee loss key executive employee adverse tel publicity news coverage email corporatesustainabilityrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark legally protect link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text reporting consist actual annual report finance report contain annual financial statement consolidated financial statement regard content management report article incorporation consist aforementioned report exception remuneration report print nonchlorine bleach fsccertifie paperf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom e roche finance report finance report